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General introduction
Emerging evidence has changed our view on preeclampsia from be-
ing a syndrome unique and confined to pregnancy to a risk marker 
for cardiovascular disease. Large epidemiological studies have shown 
that women with a history of preeclampsia have an increased risk of 
cardiovascular disease, such as ischemic heart disease, cerebrovascular 
accidents and venous thromboembolism.1 Such studies do not reveal the 
functional impact of a previous preeclampsia on several organs. This 
thesis tries to provide insight in long-term cardiovascular health and 
renal function of women with a history of preeclampsia. Risk factors for 
the development of chronic hypertension after preeclampsia are evalu-
ated and a clinical strategy for cardiovascular risk management after a 
hypertensive disorder pregnancy will be proposed. 
 
Clinical picture of preeclampsia
Pregnancy can be complicated by hypertension, either pre-existent or 
new-onset during pregnancy (table 1). Preeclampsia is a hypertensive 
disorder of pregnancy, characterized by new-onset hypertension and 
proteinuria. Preeclampsia is an important cause of maternal and fetal 
mortality and morbidity worldwide complicating approximately 2-8% 
of all pregnancies.2 It is a systemic disorder, in which several organs 
are involved, such as the liver, kidneys and brain. The role of the pla-
centa is pivotal for the development and progression of the disorder. 
After delivery the clinical syndrome usually resolves within a couple 
of days. 
Table 1: Definitions of hypertension for this thesis. 
Hypertensive disorder of pregnancy
•  Preeclampsia: a syndrome of pregnancy characterized by new-onset hypertension 
(≥140/90 mmHg) and proteinuria (≥300 mg/24 hr); diagnosed after 20 weeks of 
gestation.
•  Gestational hypertension: new-onset hypertension (≥140/90 mmHg) in preg-
nancy; diagnosed after 20 weeks of gestation.  
 Chronic hypertension
•  Pre-existent hypertension: hypertension (≥140/90 mmHg) and/or usage of 
antihypertensive drugs before pregnancy; or hypertension (≥140/90 mmHg) 
diagnosed before 20 weeks of gestation. 
•  Hypertension after pregnancy: hypertension (≥140/90 mmHg) and/or usage of 
antihypertensive drugs after first completed pregnancy.
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Figure 1 displays a pathway on how circulating soluble Flt-1 may 
cause glomerular endotheliosis in preeclampsia.  VEGF is essential 
for formation of endothelial cell fenestrae and proper functioning of 
the glomerular endothelium.7 The podocytes produce large amounts 
of VEGF and this local signalling seems critical for their adequate 
functioning and that of the glomerular endothelium.4, 8 The block-
age of VEGF by circulating soluble Flt-1 leads to detrimental effects 
on the glomerular filtration barrier. Infusion of soluble Flt-1 in mice 
or rats leads to rapid glomerular endothelial cell dysfunction and 
proteinuria.9, 10  
 
Pregnancy induces renal hyperfiltration, with an increase in glomeru-
lar filtration rate of 40-60%, resolving within a few weeks post par-
tum.11 During preeclampsia, the glomerular filtration rate is reduced 
to non-pregnant values, accompanied by a marked fall in glomerular 
ultrafiltration compared with normal pregnancy.12 After pregnancy 
a fast recovery of kidney function is observed. There is a marked 
improvement in glomerular filtration capacity in the first month post 
partum after preeclampsia.11 Although proteinuria usually resolves 
within a couple of months after delivery, microalbuminuria persists 
in about 30%.13 
c 
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Figure 1: Model of kidney dysfunction in preeclampsia
Table 2: Odds ratios (OR) of cardiovascular disease in women with a history 
of preeclampsia. 
Hypertension OR 3.7 (2.7-5.1)1
Ischemic heart disease OR 2.2 (1.9-2.5)1
Stroke OR 1.8 (1.5-2.3)1
Venous thromboembolism OR 1.8 (1.4-2.3)1
End stage renal disease OR 4.7 (3.6-6.1)14
Etiology
Endothelial dysfunction plays a central role in the etiology of pree-
clampsia. For many years, the placenta was considered to release an 
unknown factor X, causing endothelial dysfunction and subsequently 
leading to damage in a number of target organs. Basic science studies 
have unravelled several pathophysiological steps that lead to impaired 
placentation. Nowadays, we consider shallow trophoblast inva-
sion,  necessary for remodelling of the spiral arteries, a key feature in 
preeclampsia.3 Moreover, the importance of soluble Flt-1, an anti-
angiogenic factor, in the pathophysiology of preeclampsia has been 
established. A normal healthy placenta releases substances such as 
placental growth factor (PlGF) and vascular endothelial growth factor 
(VEGF). Receptors for VEGF (such as Flt-1) are present on all en-
dothelial cells and contribute to a healthy endothelium. In preeclamp-
sia, the placenta releases large amounts of soluble Flt-1, a circulating 
receptor for VEGF, which antagonizes the actions of VEGF by bind-
ing it and thus preventing VEGF from interacting with its receptor on 
the endothelium.3 This may result in systemic endothelial dysfunc-
tion, triggering the clinical symptoms of preeclampsia.  
Preeclampsia and the kidneys
The kidneys show typical histological features during preeclampsia, 
called glomerular endotheliosis. The glomerular barrier consists 
of several layers, which is impermeable for larger molecules such 
as proteins.4 Typical histological findings from kidney biopsies in 
preeclampsia are thickening and swelling of the glomerular basement 
membrane and loss of endothelial cell fenestrae.5 The glycocalyx, 
contributing to charge selectivity of the membrane, is also affected. 
Electron microscopy shows loss of podocyte foot processes, which are 
crucial to maintain the integrity of the membrane.6 All these changes 
lead to reduced permselectivity of the glomerular barrier and loss of 
proteins in the urine.  
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 cardiovascular risk exceed a certain threshold for disease during 
pregnancy triggering the development of preeclampsia. Later in life, 
ageing will lead to the development of cardiovascular disease at a 
younger age than in women who had uneventful pregnancies. 
 
Several reports support the view that pre-existing risk factors contri-
bute to the increased risk of cardiovascular disease after preeclampsia. 
However, it is still unsettled whether preeclampsia itself has a direct 
effect contributing to the development of cardiovascular disease. 
Irrespective of whether this risk profile is pre-existent or induced 
by pregnancy itself, the occurrence of a hypertensive disorder of 
pregnancy identifies women at risk for cardiovascular disease. This 
offers opportunities for prevention of cardiovascular disease in these 
women. Currently, there is no structured follow-up after a hyperten-
sive disorder of pregnancy and no guidelines for cardiovascular risk 
management in these women. 
Preeclampsia is associated with a five times increased risk of end-stage 
renal disease.14 Reports on long-term renal function after preeclamp-
sia, especially using accurate methods, are scarce. A few cross-section-
al studies evaluating kidney function several years after preeclampsia, 
did not find any difference in creatinine clearance when measured 3-6 
years post partum.15, 16 A gradual decline in renal function with age is 
observed in the general population from 30 years onwards, reflected 
by a decrease in glomerular filtration rate of 1 ml/year.17
Preeclampsia itself or concomitant risk factors, such as hypertension, 
could induce kidney damage, making the kidneys prone to acceler-
ated age-related renal function loss. 
Preeclampsia and cardiovascular disease
Women with a history of preeclampsia have an almost four times 
higher risk of chronic hypertension and a doubled risk of cardio-
vascular diseases (table 2).1, 18 These risks are observed within 10-20 
years after pregnancy in relatively young women. The life expectancy 
is reduced by approximately 6 years, mainly due to cardiovascular 
death.19 Risk factors for preeclampsia show large overlap with classi-
cal risk factors for cardiovascular disease, such as obesity, hyperin-
sulinemia and dyslipidemia. Elaborating on this, Sattar proposed the 
following theory (figure 2).20 Pregnancy can be considered as a stress 
test for the vascular and metabolic system. Women with a  preexisting 
Figure 2: Pregnancy as a stress test 
Reproduced with permission from the BMJ Publishing Group Ltd.20
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Outline of this thesis 
This thesis focuses on possible underlying mechanisms explaining 
the increased risk of cardiovascular disease after preeclampsia and 
the impact on target organs such as the cardiovascular system and 
kidneys.  
 
Chapter 2 determines the remote impact of preeclampsia on hemo-
dynamic and renal function. A group of women with a history of 
preeclampsia are studied at middle-age, on average 23 years after 
pregnancy. Chapter 3 studies cardiovascular risk factors and renal, 
endothelial and sympathetic function in women with a history of 
preeclampsia and gestational hypertension about 4 years postpartum. 
Chapter 4 explores the role of endothelial dysfunction in middle-
aged women with a history of preeclampsia evaluating microvascular 
reactivity and its relation with several cardiovascular risk factors. 
Chapter 5 elaborates on the hypothesis that women with a history 
of preeclampsia may have accelerated age-related renal function loss 
compared to women with a history of normal pregnancies. It com-
pares two different age groups, young and middle-aged women, in 
a cross-sectional study design. The same question is addressed in 
Chapter 6, after optimizing the study methods using a longitudinal 
design and inulin clearances to measure renal function.  
Chapter 7 presents a clinical strategy for cardiovascular risk ma-
nagement following a hypertensive disorder of pregnancy. Chapter 8 
 identifies, within a population of women with a history of preeclamp-
sia, metabolic and obstetric risk factors for the subsequent develop-
ment of chronic hypertension. 
Chapter 9 summarizes the main findings of this thesis. The general 
discussion highlights the implications of this thesis for future re-
search and ends with the conclusion of this thesis.
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Chapter 2
Remote hemodynamics and 
renal function in formerly 
 preeclamptic women
Julia Spaan, Timo Ekhart, Marc Spaanderman, Louis Peeters
Obstetrics & Gynecology 2009;113:853-9
PART I
Cardiovascular health
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Introduction 
Preeclampsia, a syndrome of pregnancy characterized by new onset 
hypertension and proteinuria, affects about 5-8% of all first pregnan-
cies.1 Preeclamp sia accounts for considerable maternal and associa-
ted fetal morbidity and morta lity. Recent epidemiological data have 
shown an association between preeclamp sia and cardiovascular and 
renal disease in later life.2-4 Within 10 to 20 years after a complicated 
pregnancy, these women have three to fourfold higher risk of de-
veloping chronic hypertension and a twofold higher risk of stroke, 
venous thrombo em bo lism, and ischemic heart disease compared 
with healthy parous controls.2 Later kidney disease, diagnosed by 
biopsy or the presence of end-stage renal disease, is more prevalent 
among formerly preeclamptic women compared with controls.5, 6 
Additionally, life expectancy is reduced by 3 to 9 years, with excess 
mortality mainly as a consequence of cardiovascular disease.7
The etiology of preeclampsia is only partly resolved. Impaired early-
pregnancy placentation and endothelial dysfunction seem to play 
a central role.  A large body of evidence favors the hypothesis of 
pregnancy-related hypertensive disease being superimposed upon a 
preexisting disorder.8-10 Underlying pathophysiological phenotypes 
may be hypertensive (latent or present), metabolic, auto-immuno-
logic, thrombophilic, or any combination of these.10 These disorders 
share the capacity to jeopardize both endothelial and placental func-
tion. It has been proposed that pre eclampsia relates to later cardio-
vascular disease because of shared risk factors.11, 12 However, the exact 
mechanism underlying the increased cardio vascular disease risk in 
preeclamptic women has not been unraveled yet. It is well known 
that aging negatively influences the vascular system. Aging increases 
vascular stiffness and affects renal function; however, women seem 
to be protected in the premenopausal phase.13-16 Hemodynamic and 
renal functions have not been previously studied in middle-aged, 
formerly preeclamptic women. In this study we tested the hypothesis 
that preeclampsia predisposes to remote central hemodynamic and 
renal impairments. 
Methods
We performed this cross-sectional study in 22 formerly pree - 
 clamptic women and 29 parous controls in the period of 2001  
until 2008. Participants were all white and matched for age,  
BMI and date of birth. Figure 1 illustrates the selection procedure. 
Abstract
Objective: Women with a history of preeclampsia have an increased 
risk of developing chronic hypertension and cardiovascular disease. 
However, little is known about the mechanism responsible for vas-
cular disease in formerly preeclamptic women. The aim of our study 
was to test whether preeclampsia predisposes to central hemodyna-
mic and renal impairments 20 years after pregnancy.
Methods: In this cross-sectional study, 22 formerly preeclamptic 
women and 29 parous controls participated, matched for BMI, age 
and date of birth. All women delivered in the period of 1979-1987. 
Measures included automated blood pressure, Doppler echocardio-
graphy, microalbuminuria, para-aminohippurate and creatinine 
clearances. Hypertension was defined as blood pressure at or above 
140/90 mmHg, using antihypertensive drugs, or both.
Results: Hypertension was present in 55% of the formerly preeclamp-
tic women and 7% of the women in the control group (p<.01). Mean 
arterial pressure was higher in the formerly preeclamptic women 
compared with controls (100 and 88 mmHg, respectively, p<.01). 
Peripheral vascular resistance was about 20% higher, renal vascular 
resistance about 30% higher, and renal blood flow about 15% lower in 
the formerly preeclamptic women compared with those in the control 
group (p<.05). Similar results were observed after stratification for 
hypertension in both groups.
Conclusion: Both normotensive and hypertensive middle-aged 
formerly, formerly preeclamptic women showed impaired central 
hemodynamic and renal function compared with parous controls. 
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time (45%), psychological burden (25%) and invasiveness of mea-
surements (10%). The study protocol was ap proved by the hospital 
medi cal ethical committee board. 
Hyper tension was defined as blood pressure at or above 140/90 
mmHg during the measure ment session, using antihypertensive 
drugs, or both. Women were considered postmenopausal if they had 
had 1 year without menstrual bleeding. Early-onset preeclampsia was 
defined as preeclampsia resulting in birth before gestational age of 34 
weeks.
All experiments were preceded by 1 week of standardized sodium 
intake (100 mmol sodium/day), representing the mean sodium intake 
in our population. Antihypertensive drugs were discontinued 2 weeks 
prior to the measurements. Participants did not drink caffeine- or 
alcohol-containing beverages and refrained from smoking and eating 
for at least 10 hours prior to the experiment. Measurements were 
performed in standardized conditions in a temperature-con trolled 
room (25-26 °C), with as little external disturbances as possible, 
in the mid-follicular phase (day 5 ± 2) of the menstrual period or 
randomly when postmeno pausal. The measurement session started 
at 8:00 AM with the insertion of a 20-gauge catheter into a vein of the 
right forearm to enable estimation of renal function as detailed below. 
A second catheter was inserted into a vein of the contra lateral fore-
arm to collect blood samples. Throughout the measurement session, 
participants were laying on their back on a comfortable bed. After 
an acclimatization period of 30 minutes, we recorded arterial blood 
pressure and heart rate in supine position at 3-minute intervals using 
a semi-automatic oscillometric de vice (Dinamap Vital Signs Monitor 
1846, Critikon, Tampa, FL). 
Effective renal plasma flow was measured by continuous infusion of 
para-amino hip pu rate sodium (MSD, West Point, PA). We used the 
creatinine clearance as an estimate for glomerular filtration rate as 
inulin was not available due to manufactural problems. Both varia bles 
were corrected for body surface area and expressed in ml/min/1.73 m2. 
Effective renal blood flow was obtained by dividing the effective renal 
plasma flow by (1-hematocrit). Renal vas cular resistance (dyne.s/
cm5/1.73m2) was ob tained by dividing mean arterial pressure by 
effective renal blood flow. At least 2 hours after the initiation of the 
para-aminohippurate sodium infusion, we collected blood samples 
We  retrieved cli ni cal infor ma tion for all women who delivered after a 
preeclamptic pregnancy in the period be tween 1979 and 1987 at the 
Department of Obstetrics of the Academic Hospital of Maastricht in 
the Netherlands. Pre eclamp sia was defined according to the crite-
ria of the Report of the National High Blood Pressure Education 
Program Work ing Group on High Blood Pressure in Pregnancy.1 An 
uncomplicated pregnancy was defined as a term single ton pregnancy 
without complications such as fetal growth restriction, pregnancy-
induced hypertension or gestational diabetes. For every primiparous 
preeclamptic wo man, we selected chronologically from the birth 
register the next two matching primiparous women with uncompli-
cated pregnancies and deliveries. From the women identified, four 
women died in the period elapsed since their pregnancies; three from 
cancer, and one formerly preeclamptic woman had had a fatal cardiac 
event. Eight formerly preeclamptic women were excluded for medi-
cal reasons, namely non-insulin-dependent diabetes mellitus (n=2), 
cancer therapy (n=3), chronic corticosteroid use (n=1) and chronic 
renal failure (n=2) due to nephrosclerosis and chronic pyelonephritis. 
Eventually, 44 for merly preeclamptic  women and 72 parous con-
trols were invited to parti ci pate in this study. From these wo men, 
22 formerly preeclamptic women (50%) and 29 controls (40%) gave 
inform ed consent to participate. Main reasons for refusal were lack of 
Included from birth register 
Died n=2 (3%)  
Excluded n=8 (12%) 
Renal failure n=2 
Diabetes mellitus n=2 
Others n=4 
Invited to participate 
Informed consent n=22 (50%) 
Refusal n=43 (60%) 
PE group n=67 Control group n=113 
Died n=2 (2%)  
No recent address n=39 (35%) No recent address n=13 (20%) 
Informed consent n=29 (40%) 
Refusal n=22 (50%)  
Control group n=72 PE group n=44 
Figure 1: Flowchart of the selection procedure. 
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Table 1: Characteristics of the study population.
Controls 
(n=29)
Formerly pre eclamptic 
(n=22)
p-value
Age (y) 49.8 ± 3.9 49.0 ± 3.9 0.48
BMI (kg/m2) 25.5 ± 3.5 25.0 ± 3.6 0.63
Smoking, n (%) 10 (35) 3 (14) 0.09
Postmenopausal, n (%) 5 (17) 8 (36) 0.12
Hypertension, n (%) 2 (7) 12 (55) <0.01
Stroke, n (%) 1 (3) 2  (9) 0.40
Thrombosis, n (%) 1 (3) 3  (13) 0.18
GA at birth (wks) 40 4/7 (38-42) 34 6/7 (27-43) <0.01
Birth weight (g) 3574 (2730-4500) 1801 (880-3350) <0.01
Early-onset PE, n (%) - 9 (41)
Parity 2.2 (1-4) 1.7 (1-3) 0.04
Recurrent PE, n (%) - 5 (23)
FU (y) 23 (20-28) 23 (20-28) 0.12
Data are detailed as mean ± SD, mean (min-max) or n (%). BMI, body mass index; 
GA, ges ta tional age; PE, preeclampsia; FU, follow-up time, years elapsed since pree-
clamptic or control pregnancy.  
Results
Table 1 lists the characteristics of our study population. Both groups 
were comparable with respect to age, BMI at measurement, and 
follow-up time. Mean age was 49.8 (range: 42.2-59.0) for controls 
and 49.0 (range: 42.7-58.1) years for formerly preeclamptic women. 
Eight for merly pre eclamptic women (36%) and five women in the 
control group (17%) were postmeno pau sal. None of the women used 
hormone replacement therapy. Twelve formerly preeclamptic women 
(55%) and two women in the control group (7%) had hypertension 
at the time of measurement (RR 7.9; 95%CI 2.0-31.8), with nine 
formerly preeclamptic women using antihyper tensive medication at 
the time of recruit ment. We diagnosed hyper tension at the time of 
the measurement session in two women in the control group. Two 
formerly preeclamptic women and one woman in the control group 
had a history of stroke. Three formerly preeclamptic women and 
one woman in the control group had a history of thrombosis. Nine 
for merly pre eclamptic women (41%) had a history of early-onset 
preeclampsia, and five (23%) had recurrent preeclampsia in their 
subsequent pregnancies. None of the women in the control group had 
hypertensive complications during subsequent pregnancies. 
for the later measurement of the circulating levels of para-aminohip-
purate and creatinine. Creatinine (µmol/l) was measured by standard 
chemical techniques. An extra blood sample was obtained to measure 
hematocrit (volume %). Creatinine clearance was calculated from the 
24-hours creatinine output during the day before measurement. In 
this col lection, we also measured albumin excretion. Micro albu min-
uria was defined as urinary albumin excretion rate higher than 3.5  
g/mol creatinine (BN ProSpec nephelometer). 
Echocardiography to assess cardiac function was performed in semi-
left lateral po si tion after 5 minutes of rest, using a cross-sectional, 
phased-array echocardiographic Doppler system.17 Cardiac output 
(CO, l/min) was calculated by multi plying stroke volume (ml) by 
heart rate. In this formula, heart rate was obtained by tak ing the re-
ciprocal of the mean of five consecutive R-R inter vals on the electro-
cardiogram. Stroke volume was calculated by multiplying the aortic 
velocity integral and the aor tic area. Aor tic flow was measured across 
the aortic valves from an apical approach. The ave rage area under 
the aortic velocity curve (aortic velocity integral) of five con se cutive 
ejections was used to calculate stroke volume. Aortic valve dia me ter, 
necessary for the calculation of the aortic area, was measured off-line 
at the ori fice during systole using M-mode. Cardiac index (CO,  
l/min/m2) was used to correct for body surface area. Total peripheral 
vascular resistance was calculated by 80 times mean arterial pressure 
divided by CO. The value used for mean arterial pressure was ob-
tained by blood pressure measurement during the CO measurement 
and was calcu lated as the mean of three consecutive record ings. An 
estimate for arterial compliance (ml/mmHg) was obtained by di vi -
ding stroke volume by pulse pressure.
Data distribution was evaluated using histograms and Q-Q plots. 
Homogeneity of variance was tested by Levene’s test. Differences be-
tween groups were tested by Student t-test or Mann-Whit ney U-test. 
Binary outcomes were tested by chi-square test. Using both multiple 
logistic and linear regression analysis, we adjusted for postmenopau-
sal state. We further analyzed our data after stra tifi ca tion for hy per-
tension by one-way analysis of variance followed by Dunnet’s test or 
the Kruskal-Wallis test followed by Dunn’s test. A p-value <.05 was 
considered statistically sig ni ficant. Data are presented as mean with 
standard deviation or median with interquartile range.
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Table 3: Comparison of normotensive and hypertensive formerly preeclamptic 
(PE) women with parous controls.
Controls
(n=29)
Normo tensive
PE (n=10)
Hyper tensive
PE (n=12)
Blood pressure (mmHg) 
Systolic blood pressure 117 ± 15 124 ± 14 139 ± 16*
Diastolic blood pressure 72 ± 9 75 ± 10 84 ± 12*
Mean arterial pressure 88 ± 10 95 ± 11 104 ± 13*
Pulse pressure 45 ± 11 49 ± 9 55 ± 13†
Heart rate (bpm) 66 ± 7 66 ± 9 71 ± 6
Cardiovascular
Cardiac output (l/min) 5.0 ± 0.7 4.6 ± 0.8 4.9 ± 0.6
Cardiac index (l/min/m2) 2.8 ± 0.4 2.7 ± 0.4 2.8 ± 0.4
LV ejection fraction (%) 61 (58-64) 64 (58-67) 65 (59-66)
E/A-ratio 1.1 (1.0-1.5) 1.4 (1.1-1.6) 1.1 (0.9-1.3)
LV mass-index (g/m2) 76 (67-88) 79 (69-88) 90 (79-88)
TPVR (dyne.s/cm5) 14.6 ± 1.9 17.1 ± 2.5* 17.9 ± 2.5*
Arterial compliance (ml/mmHg) 1.6 ± 0.3 1.3 ± 0.2† 1.3 ± 0.4*
Renal function
Creat Clear (ml/min/1.73m2) 100 ± 19 91 ± 11 86 ± 18
ERPF (ml/min/1.73m2) 463 ± 83 399 ± 66† 398 ± 60†
ERBF (ml/min/1.73m2) 768 ± 138 671 ± 122 678 ± 90
RVR (.100 dyne.s/cm5/1.73m2) 95 ± 20 118 ± 35† 125 ± 21*
Microalbuminuria (>3,5 g/mol) 3 (10%) 0 ( - ) 2 (17%)
Data are presented as mean ± SD, median (IQR) or n (%). PE, preeclampsia; bpm, 
beats per minute; LV, left ventricle; E/A, early and late diastolic peak flow velocity; 
TPVR, total peri pheral vascular resistance; Creat Clear, Creatinine clearance; ERPF, 
effective renal plasma flow; ERBF, effective renal blood flow; RVR, renal vascular 
resistance. 
* p-value <.01, compared with controls, † p-value <.05, compared with controls.
Table 3 illustrates the comparison of hemodynamic and renal 
variables between formerly preeclamptic women, with or  with out 
hypertension, and women in the control group. Blood pressure 
variables and creatinine clearance in nor motensive formerly pree-
clamptic women were intermediate be tween the values observed 
in hyper tensive formerly preeclamptic women and women in the 
control group. Like hypertensive formerly preeclamptic women, 
the  normotensive formerly preeclamptic women also differ ed from 
controls by higher total peripheral and renal vas cular re sist an ce and 
a lower arterial compliance. Left ventricular mass-index tended to be 
higher only in hypertensive formerly preeclamptic women. 
Table 2: Cardiovascular and renal variables measured 23 years after pregnancy  
in formerly preeclamptic women and parous controls.
Controls  
(n=29)
Formerly pre eclamptic  
(n=22)
p-value
Blood pressure (mmHg)
Systolic blood pressure 117 ± 15 132 ± 17 0.001
Diastolic blood pressure 72 ± 9 80 ± 12 0.005
Mean arterial pressure 88 ± 10 100 ± 12 0.001
Pulse pressure 45 ± 11 52 ± 11 0.021
Heart rate (bpm) 66 ± 7 69 ± 8 0.288
Cardiovascular
Cardiac output (l/min) 5.0 ± 0.7 4.8 ± 0.7 0.268
Cardiac index (l/min/m2) 2.8 ± 0.4 2.8 ± 0.4 0.583
LV ejection fraction (%) 61 (58-64) 65 (59-66) 0.145
E/A-ratio 1.1 (1.0-1.5) 1.2 (1.0-1.5) 0.969
LV mass-index (g/m2) 76 (67-88) 88 (72-97) 0.097
TPVR (dyne.s/cm5) 14.6 ± 1.9 17.5 ± 2.5 <0.001
Arterial compliance (ml/mmHg) 1.6 ± 0.3 1.3 ± 0.3 <0.001
Renal function
Creat Clear (ml/min/1.73m2) 100 ± 19 88 ± 15 0.023
ERPF (ml/min/1.73m2) 463 ± 83 399 ± 61 0.003
ERBF (ml/min/1.73m2) 768 ± 138 675 ± 103 0.011
RVR (.100 dyne.s/cm5/1.73m2) 95 ± 20 122 ± 28 <0.001
Microalbuminuria (>3,5 g/mol) 3 (10%) 2 (9%) 0.881
Data are presented as mean ± SD, median (IQR) or n (%). bpm, beats per minute; LV, 
left ventricle; E/A, early and late diastolic peak flow velocity; TPVR, total peri pheral 
vascular resistance; Creat Clear, Creatinine clearance; ERPF, effective renal plasma 
flow; ERBF, effective renal blood flow; RVR, renal vascular resistance. 
Table 2 lists the cardiovascular and renal variables comparing both 
study groups. Similar results were found after adjustment for post-
menopausal state (not presented). Formerly preeclamptic women had 
higher systo lic, diastolic and mean arterial blood pressure as com-
pared with women in the control group. Cardiac function did not dif-
fer be tween the study groups. Formerly preeclamptic women differed 
from women in the control group by a 20% higher total peripheral 
vascular resistance and a lower arterial compliance. Renal vascular 
resistance was more than 30% higher and effec tive renal plasma flow 
about 15% lower in formerly pre eclamptic women compared with 
women in the control group. Creatinine clearance was lowered in 
formerly preeclamptic women relative to women in the control group. 
The incidence of microalbu minuria was similar in both groups. 
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concept that these women may have an altered vascular function 
already in their first years of life. During growth and development, 
genetic factors act in concert with environmen tal factors to determine 
the final functional capa city of the vas cular system.28, 29 Low-birth 
weight, pre eclampsia, and essential hyper tension seem to share a 
reduced vascular functional reserve capacity, for example, density of 
the capillary bed seems to be reduced in those conditions.30-32 In this 
view, preeclamptic women can be considered to represent a sub-
group of women predestined to develop hypertension irrespective of 
pregnancy. 
This study has certain limitations. Firstly, the recruitment of the 
women in the control group may have been hampered by some selec-
tion bias because women with certain health pro blems may have 
been more eager to par tici pate in this study than their counter parts 
without any health problems. As the latter could have an attenuating 
effect on po ten tial differences with formerly preeclamptic women, 
this effect may only have reduced the already marked differences 
observed in this study. Secondly, more than 20 years elapsed since 
either the preeclamptic or uneventful pregnancy. Since then, health 
in both groups has been influenced by a wide range of demographic 
and lifestyle factors, which could have had an unknown effect on the 
variables measured. By matching the controls for age and BMI, we in-
tended to minimize the impact of obesity and its associated metabolic 
abnormalities, such as insulin resistance and dys lipidemia. A strategy 
to deal with most shortcomings would be to follow women longitudi-
nal ly with respect to age-related hemodynamic changes. Preeclampsia 
may identify a subgroup of women at risk of accele rated aging, 
enabling exploration of the mechanism of accelerated cardiovas cular 
aging. 
In summary, in this cross-sectional study, we found evidence for im-
paired hemodynamic and renal function in both normotensive and 
hyper tensive middle-aged, formerly pre eclamp tic women. These data 
support the view that formerly preeclamptic women would benefit 
from surveillance of blood pressure. 
Discussion
In this study, we observed differences in central hemodynamics and 
renal function between formerly preeclamptic women and parous 
con trols 23 years after pregnancy. The he mo dy na mic pattern we 
observed in former ly pre eclamptic women (high blood press ure, in-
creased peripheral vascular resistance and a normal cardiac output) is 
consistent with the changes observed in so-called volume-dependent 
es sential hy per ten sion.18, 19 The kidneys play a central role in this 
theory because they adjust the setpoint for blood pressure by their 
effect on sodium homeostasis. The exact pathophysio lo gy of essential 
hy per tension is complex and only partly unraveled. The develop-
ment of hyper tension is the ultimate outcome of activated pathways 
involving systemic and re nal vasoconstriction. These include hyper-
activity of the sym pa thetic ner vous sys tem, hyperactivity of the renin-
angiotensin system and en do thelial dysfunc tion.20 Our data suggest 
that renal vaso con striction plays a central role in the pa tho ge nesis of 
hypertension in formerly preeclamp tic women. This concept is sup-
port ed by the raised renal vascular resistance and reduced crea ti nine 
clea ran ce in for merly preeclamptic women compared with controls, 
a difference already detected in normotensive formerly preeclamp-
tic women. The renal impairment observed could be due to lower 
nephron number and glomerulosclerosis.21, 22 We observed a low in-
cidence of microalbuminuria in both groups; however, other studies 
report an increased incidence of microalbuminuria several years after 
preeclamptic pregnancy.23, 24 
The in termediate position of the group of normotensive formerly 
preeclamptic women between, on the one hand hypertensive for-
merly preeclamptic women and, on the other hand, the women in 
the control group, can be interpreted as prehypertension. The lat-
ter is characterized by loss of arterial compliance accompanied by 
raised systemic and renal vascular resistance and precedes manifest 
hypertension in high-risk groups such as ado lescents of hypertensive 
parents.25-27 Our data suggest that impaired hemodynamic function 
precedes the onset chronic hypertension in formerly preeclamptic 
women. However, these data do not exclude the possibility that these 
impairments reflect an end-stage in the subgroup of normotensive 
formerly preeclamptic women. 
Whether or not the observed changes were present before the pree-
clamptic pregnancy is obscure. There is increasing evidence for the 
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Abstract
Objective: Women with a history of preeclampsia or gestational 
hypertension have an increased risk of cardiovascular disease. 
Underlying cardiovascular risk factors, persistent endothelial dys-
function or sympathetic overactivity may contribute to this risk. 
We studied markers of cardiovascular disease risk in nonpregnant 
women with a history of hypertension in pregnancy. 
Methods: Women with a history of preeclampsia (n=39), gestational 
hypertension (n=27), and normal pregnancies (n=35) were  studied 
2-12 years after delivery. Laboratory measures included plasma 
fasting lipids, glucose, insulin, creatinine and urinary albumin-to-
creatinine ratio. Blood pressure was measured by 24-h ambulatory 
blood pressure monitoring, endothelial function by flow-mediated 
dilatation and sympathetic activity by both head-up tilt test and cold 
pressor test, including the response of the circulating renin-angioten-
sin system to tilt testing. 
Results: Compared with women who had previous normal pregnan-
cies, women with a history of preeclampsia or gestational hyperten-
sion have higher ambulatory blood pressure, body mass index and 
relative insulin resistance. Glomerular filtration rate, albumin-to-
creatinine ratio, endothelial function and sympathetic activity was 
similar between the three groups. 
Conclusion: Women with a history of preeclampsia or gestational 
hypertension have features of the metabolic syndrome which are 
presumably present already before pregnancy, predisposing them to 
hypertensive disorders of pregnancy and later cardiovascular risk. In 
this study, we found no evidence for early renal damage, endothelial 
dysfunction or sympathetic overactivity in the post partum state.  
Chapter 3
Markers of cardiovascular 
 disease risk after hypertension 
in pregnancy
George Mangos, Julia Spaan, Saiyini Pirabhahar, Mark Brown
Journal of Hypertension 2012;30:351-8
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 endothelial dysfunction post partum may contribute to their in-
creased cardiovascular disease risk.10-12 Sympathetic overactivity is 
proposed to be one of the contributors to preeclampsia and is one 
of the mechanisms involved in the development of essential hyper-
tension.13, 14 Although increasing research has examined the factors 
involved in the propensity for women with preeclampsia to develop 
later cardiovascular disease, less work has been conducted in women 
with a history of gestational hypertension alone and few studies 
have examined endothelial function or sympathetic nervous system 
 activity in these women.
The aim of this study was, therefore, to test 2-12 years after delivery 
whether women who had preeclampsia or gestational hypertension 
during their pregnancy have a greater cluster of cardiovascular risk 
abnormalities than women who had a normal pregnancy; evidence 
of endothelial dysfunction, sympathetic (over)activity and/or renin-
angiotensin system activation; and evidence of subtle abnormalities of 
renal function.  
Methods
We recruited 101 women who were of 2-12 years postpartum us-
ing a database of all pregnant women consulted to our department 
for management of hypertension or renal disease during pregnancy, 
maintained since 1988. Twenty seven women had prior gestational 
hypertension, 39 had prior preeclampsia and 35 had previous normal 
pregnancies. We excluded women who were pregnant, had diabetes 
mellitus, prior essential hypertension in pregnancy or renal disease. 
We used the Australasian Society for the Study of Hypertension in 
Pregnancy consensus statement criteria for the diagnosis of gesta-
tional hypertension and preeclampsia.15 Gestational hypertension was 
defined as new onset of blood pressure ≥140/90mmHg after the 20th 
week of gestation in women with no history of hypertension, renal 
or cardiovascular disease, with no clinical or laboratory features of 
preeclampsia. Preeclampsia was defined as new onset of hypertension 
after the 20th week of gestation with proteinuria confirmed by spot 
urine protein-to-creatinine ratio >30mg/mmol. Normal postpartum 
women were from the same local community with no history of 
hypertension, renal disease, preeclampsia or gestational hyperten-
sion. Informed written consent was obtained from all women be-
fore they commenced the study. The study protocol was approved 
by the South East Sydney Area Health Human Research Ethics 
Introduction
About 10% of all pregnancies are affected by hypertensive disorders 
worldwide. These include chronic hypertension, gestational hyperten-
sion and preeclampsia. Several studies have shown that gestational 
hypertension and preeclampsia are associated with future cardio-
vascular and renal disease.1, 2 The mechanism for this increased risk 
is unclear; however, hypertension in pregnancy and later vascular 
disease share common risk factors such as diabetes, dyslipidaemia 
and obesity.  
Women who have had pregnancies complicated by hypertension are 
at high risk of developing cardiovascular disease. A Norwegian study 
published in 2001 reported almost three times higher risk of death 
in general and an eight times higher risk of cardiovascular death in a 
26-year follow-up (median 13 year) of women with a history of pree-
clampsia who delivered preterm, when compared with women who 
did not have preeclampsia.3 The presence of a history of preeclampsia 
in combination with premature delivery and/or intra-uterine growth 
restriction is associated with a seven-fold increased risk of future 
cardio vascular disease.4 
The persistence of metabolic abnormalities after preeclampsia could 
be one of the factors contributing to the increased risk of cardiovas-
cular disease in this group of women.4 It is not entirely clear whether 
it is hypertension per se during pregnancy or the more specific 
placental disorder of preeclampsia that predisposes to later cardio-
vascular risk. According to Jonsdottir et al., the relative risk of dying 
from coronary heart disease was significantly higher among women 
who had eclampsia or preeclampsia than in women with gestational 
hypertension alone.5 Factors common to cardiovascular disease and 
preeclampsia include obesity, insulin resistance, and inflammation. 
Elevated fasting insulin and glucose levels have been demonstrated 
during glucose tolerance tests in women with preeclampsia;6 also, 
women with a history of preeclampsia have higher serum concentra-
tions of fasting lipids, insulin and coagulation factors post partum 
than do controls matched for body mass  
index.7-9 
  
Several regulatory mechanisms have been implicated in the patho-
genesis of preeclampsia. Endothelial dysfunction is a hallmark 
of the disease and several authors have suggested that persistence of 
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in systemic parameters, arterial blood pressure was measured every 
5 min by a Dinamap Portable Vital Signs Monitor 8100 (Critikon, 
Tampa, Florida, USA) on the left calf. Two baseline blood flow re-
cordings were performed before the commencement of ischaemia. 
The baseline blood flow was measured by inflating the wrist cuffs 
to 30 mmHg above systolic blood pressure for 1 min, followed by 
venous cuff pressure to 40 mmHg.  The FBF was then measured for 3 
mins and the average of five slopes was recorded as the baseline blood 
flow. All the cuffs were deflated before ischaemia to achieve com-
plete return of normal circulation. Limb ischaemia was achieved by 
inflating the venous cuff on the left arm to 40 mmHg above systolic 
blood pressure for 10 mins. At 9 min, both wrist cuffs were inflated 
to 30 mmHg above systolic blood pressure before the FBF measure-
ment was commenced.  FBF was measured for 3 mins after the release 
of arterial occlusion. Flow-mediated dilatation was measured as the 
ratio of flow in the ischaemic arm to that of the control arm (right 
arm), expressed as the percentage of change from baseline. This 
technique controls for changes in systemic blood flow due to other 
mechanisms.17, 18
Tilt table testing: sympathetic activity and renin-aldosterone 
responses
Hemodynamic and hormonal responses to tilt were assessed by 60o 
head-up tilt on a tilt table. Participants were asked to lie supine on 
a tilt table for 10 mins. A Finapres continuous blood pressure cuff 
(Ohmeda 2300, Ohio, USA) was placed on the left hand middle finger 
to monitor changes in mean arterial pressure (MAP) and heart rate 
(HR) throughout the study.19 These data were acquired by a personal 
computer running Acknowledge for Windows software (Biopac 
Systems Inc., Goleta, California, USA). The hand was placed at the 
level of the heart. After 10 mins in supine position, patients were 
tilted upwards to 60o. The left hand was placed on a height adjustable 
table to the level of heart. A cannula was placed in a left antecubital 
vein to collect blood for aldosterone and renin at 8 min (before tilt 
up) and at 18 min (at 60o).
Cold pressor test
Women were asked to lie in a supine position for 10 min, then place 
their right foot in a bucket containing 4o C water for 2 min. Four 
(17%) women in the normal pregnancy group and six (26 %) in the 
pree clampsia group did not complete the test because of  discomfort 
 Committee-Southern Section (reference number 00/24 Brown). All 
women came to the research centre on two consecutive days during 
the follicular phase of their cycle. The study was carried out in a quiet, 
temperature controlled room.
Day 1: Blood pressure and metabolic measurements
First trimester blood pressure and weight from the index pregnancy 
were recorded from antenatal records; first trimester data were availa-
ble in 76 and 60% of all cases, respectively. Full medical and obstetric 
histories were taken. These included age, smoking, oral contraceptive 
use, history of hypertension in subsequent pregnancies and gestation 
at delivery. Women were asked to fast for 12 hours before the blood 
collection. Blood was collected for fasting lipids, glucose, insulin and 
renal function. Homeostasis model assessment (HOMA) score was 
calculated by fasting insulin times fasting glucose divided by 22.5.16 
eGFR was estimated using the Cockcroft–Gault formula. Mid stream 
urine was collected for albumin, protein and creatinine. Urinary 
calcium and sodium were determined to give an indication of dietary 
intake. Upper arm circumference was measured and an appropri-
ate blood pressure cuff was used, a ‘large’ adult cuff was chosen if 
mid-upper arm circumference ≥33cm. Blood pressure was measured 
three times after 15 mins sitting with a mercury sphygmomanometer. 
A 24-h ambulatory blood pressure monitor (Space Lab 90207) was 
fitted before women left the centre. They were asked to perform their 
normal activities for the 24-h period while the machine recorded 
their blood pressure every 30min. Their sleep and awake periods were 
recorded from their diaries.
Day 2: Physiological Studies
Measurement of vascular reactivity by flow mediated dilatation 
All studies were carried out in a quiet, temperature-controlled (22-24 
oC) room. Women were asked to lay supine during the measurement 
of forearm blood flow (FBF). We used strain gauge plethysmography 
to assess blood flow in the forearm resistance arteries. This has been 
described in detail elsewhere.17, 18 In brief, the forearm circumference 
was measured and an appropriate size strain gauge fitted 7cm below 
the olecranon in both forearms. Wrist cuffs were placed to both arms 
to arrest blood circulation to the hands during the FBF measure-
ments. Upper arm cuffs were placed on both arms and the arms were 
elevated to 45o (at the heart level) with the assistance of a height-
adjustable table and foam under the elbow. To assess for the changes 
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Table 1: Baseline characteristics in women with a history of normal  pregnancy, 
preeclampsia and gestational hypertension.
N (n=35) PE (n=39) GH (n=27)
Age at study (years) 38 ± 6 37 ± 6 36 ± 6
Years postpartum 4.3 (2.8-7.0) 3.8 (2.5-5.0) 2.9 (2.2-6.0)
Multiparous, n(%) 30 (86) 26 (67) 15 (56)*
≥2 miscarriages, n(%) 6 (17) 6 (15) 4 (15)
Delivery <37 weeks, n(%) 2 (6) 18 (46)* 4 (15)
IUGR <p10, n(%) 1 (3) 10 (26)* 3 (11)
Smoking during pregnancy, n(%) 2 (6) 2 (5) 2 (7)
Current smoker, n(%) 2 (6) 2 (5) 3 (11)
First trimester weight (kg) 61 ± 9 65 ± 14  69 ± 13 
Current weight (kg) 64 ± 9 69 ± 12 73 ± 16*
Difference in weight (kg) 4 ± 5† 5 ± 8† 4 ± 6†
First trimester BMI (kg/m2) 22.1 ± 2.5 24.1 ± 5.1 25.0 ± 4.8 
Current BMI (kg/m2) 23.7 ± 2.8 25.6 ± 4.3 27.1 ± 5.4*
Difference in BMI (kg/m2) 1.6 ± 1.9† 2.0 ± 2.8† 1.3 ± 2.3†
Current hypertension, n(%) - 1 (3) 2 (7)
N: normal pregnancy, PE: preeclampsia, GH: gestational hypertension, IUGR: intra-
uterine growth restriction, BMI: body mass index.
* p< 0.05  versus normal pregnancy, † p<0.05 current versus first trimester 
Table 2: Metabolic and cardiovascular risk factors in women with a history of 
normal pregnancy, preeclampsia and gestational hypertension.
N (n=35) PE (n=39) GH (n=27)
Total-cholesterol (mmol/l) 4.9 ± 0.7 5.0 ± 0.8 5.1 ± 1.0
Triglycerides (mmol/l) 0.8 ± 0.4 1.0 ± 0.8 1.1 ± 0.7
HDL-cholesterol (mmol/l) 1.4 ± 0.3 1.4 ± 0.3 1.3 ± 0.3
LDL-cholesterol (mmol/l) 3.1 ± 0.7 3.1 ± 0.6 3.1 ± 0.7
Glucose (mmol/l) 4.9 ± 0.5 4.8 ± 0.6 5.2 ± 0.6
Insulin (mU/l) 5 (4-7) 7 (5-11)** 7 (5-11)**
HOMA-score 1.2 (0.9-1.5) 1.5 (1.2-2.1)* 1.7 (1.1-2.5)**
Potassium (mmol/l) 4.0 ± 0.3 3.9 ± 0.3 4.0 ± 0.3
Creatinine (mmol/l) 64 ± 11 67 ± 10 66 ± 11
eGFR (mmol/l) 109 ± 25 113 ± 27 120 ± 24
Protein:creatinine (mg/mmol) 9 (7-13) 8 (7-10) 10 (7-13)
Albumin:creatinine (mg/mmol) 1.0 (0.6-1.9) 1.0 (0.7-1.5) 1.1 (0.9-1.6)
Calcium:creatinine (mmol/l) 0.28 0.21 0.20
Sodium:creatinine (mmol/l) 13 11 11
N: normal pregnancy, PE: preeclampsia, GH: gestational hypertension, HDL: high 
density lipoprotein, LDL: low density lipoprotein, HOMA: homeostasis model assess-
ment, eGFR: estimated glomerular filtration rate.
p-values presented are corrected for oral contraceptive use.
* p< 0.05  versus normal pregnancy, **p<0.01 versus normal pregnancy
(p=0.48) and they were excluded from analysis. A Finapres cuff 
(Finapres Medical Systems, Amsterdam, the Netherlands) was placed 
on the left hand middle finger to measure changes in MAP and HR dur-
ing the cold stimulus. This was done at the end of the study morning.
Statistical analysis
Data were expressed as mean and standard deviation or median and 
interquartile range, unless stated otherwise. Figures show mean and 
standard error of the mean. Groups were compared using one-way 
analysis of variance (ANOVA) followed by Dunnett test or Kruskal-
Wallis test followed by Mann-Whitney U-test with Bonferroni correc-
tion. Categorical data were tested using chi-square test. Adjustments 
for oral contraceptive pill use were made by multiple linear regression 
analysis after log transformation of the skewed variables. Repeated 
measurements were analysed by paired t-test or repeated measures 
ANOVA as appropriate.
Results
Baseline characteristics 
The baseline characteristics of the women are reported in Table 1. 
Women were studied approximately 3-4 years post partum and were 
of similar age. More women with a history of normal pregnancy or 
preeclampsia were multiparous compared with women with a his-
tory of gestational hypertension. There was no difference between 
the groups in the proportion of smokers. The women with a history 
of gestational hypertension were heavier, with a higher body mass 
index at their post-partum evaluation, compared with the normal 
group; this was of border significance for women with a history of 
preeclampsia (p=0.09). A similar trend was observed for the weight 
and body mass index in first trimester pregnancy (p=0.08 and p=0.10, 
respectively). Weight gain was present in all three groups, when 
studying the difference between current and first trimester weight or 
body mass index. In the preeclampsia group, 46% had a history of a 
delivery before 37 weeks of gestation, 26% had a pregnancy compli-
cated by intrauterine growth restriction and 38% of the multiparous 
women had preeclampsia during more than one pregnancy. In the 
gestational hypertension group, 60% of the multiparous women had 
gestational hypertension during more than one pregnancy. Current 
oral contraceptive pill use was higher in the gestational hypertension 
group (N=26%, PE=13% and GH=44%, p=0.04). None of the women 
were diabetic or used lipid lowering drugs. 
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Blood pressure
Table 3 shows the blood pressure measurements. First trimester blood 
pressure was higher in women who had gestational hypertension or 
preeclampsia in that pregnancy compared with women who had nor-
mal pregnancy. These changes persisted postpartum when measured 
by either mercury sphygmanometry or 24-h ambulatory blood pres-
sure monitoring (ABPM). Both awake and sleep ABPM was higher 
in women with a history of gestational hypertension or preeclampsia 
compared with women with normal pregnancies. High blood pres-
sure was present in 9%, 15% and 25% of all cases diagnosed by awake 
ABPM (>135/85 mmHg, p=0.15) and in 9%, 10% and 29% of all 
cases diagnosed by sleep ABPM (>125/75 mmHg, p=0.03) in women 
with a history of normal pregnancies, preeclampsia and gestational 
hypertension, respectively. Excluding the women with known chronic 
hypertension (n=3) showed comparable findings for the blood pres-
sure measurements. 
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Figure 1: Flow-mediated dilatation
Forearm blood flow (FBF) response to occlusion in women with a history of normal 
 pregnancy (N, n=22), preeclampsia (PE, n=23) and gestational hypertension (GH, n=15).
Metabolic and cardiovascular risk markers 
Metabolic and cardiovascular risk factors are presented in table 2 
with p-values adjusted for oral contraceptive pill use. No differences 
in lipid profile were observed among the three groups. In both the 
gestational hypertension and preeclampsia groups, women were 
relatively insulin resistant, as demonstrated by higher insulin levels 
and HOMA scores, compared with the normal group. There was a 
non-significant accompanying trend in fasting blood glucose. No 
differences in renal function were present, with similar values for 
glomerular filtration rate, serum creatinine, potassium and urinary 
protein- or albumin-to-creatinine ratio. Urinary sodium was similar 
among groups, whereas the urinary calcium showed a trend to be 
lower in gestational hypertension and preeclampsia (p=0.09). 
Table 3: Mercury blood pressure and 24-h ambulatory blood pressure monitor-
ing in women with a history of normal pregnancy, preeclampsia and gestational 
hypertension.
N (n=35) PE (n=39) GH (n=27)
Mercury
Current SBP (mmHg) 115 ± 12 121 ± 20 124 ± 11*
Current DBP (mmHg) 72 ± 9◊ 79 ± 8**◊ 79 ± 10*
First trimester SBP (mmHg) 113 ± 11 119 ± 10* 120 ± 9*
First trimester DBP (mmHg) 66 ± 9 71 ± 8* 76 ± 8**
ABPM
24-hr average SBP (mmHg) 111 ± 9 118 ± 9** 120 ± 9**
24-hr average DBP (mmHg) 69 ± 7 74 ± 7** 76 ± 7**
24-hr average MAP (mmHg) 83 ± 7 89 ± 8** 91 ± 8**
Awake SBP (mmHg) 113 ± 10 120 ± 11** 121 ± 10**
Awake DBP (mmHg) 71 ± 8 76 ± 9* 78 ± 8**
Awake MAP (mmHg) 85 ± 8 91 ± 9* 93 ± 9**
High Awake ABPM (>135/85 mmHg) 3 (9) 6 (15) 7 (25)
Sleep SBP (mmHg) 102 ± 10 108 ± 9* 111 ± 11**
Sleep DBP (mmHg) 61 ± 9 65 ± 8 68 ± 10**
Sleep MAP (mmHg) 75 ± 9 80 ± 8* 82 ± 10**
High Sleep ABPM (>125/75 mmHg) 3 (9) 4 (10) 8 (29)*
Awake-sleep MAP fall (%) 12 ± 11 12 ± 10 11 ± 12
Sleep hours 7 7 7
N: normal pregnancy, PE: preeclampsia, GH: gestational hypertension, ABPM: am-
bulatory blood pressure monitoring, SBP: systolic blood pressure, DBP: diastolic blood 
pressure, MAP: mean arterial pressure.
* p<0.05 versus normal pregnancy, ** p<0.01 versus normal pregnancy, ◊ p<0.05 cur-
rent versus first trimester 
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Figure 2: Tilt testing
a) Change in mean arterial pressure (MAP) during tilt testing in women with a 
history of normal pregnancy (N, n=22), preeclampsia (PE, n=22) and gestational 
hypertension (GH, n=16).
b) Change in heart rate (HR) during tilt testing in women with a history of normal 
 pregnancy (N, n=22), preeclampsia (PE, n=22) and gestational hypertension (GH, n=16).
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Vascular Reactivity 
Baseline FBF was 4.33 (3.53-5.31), 4.61 (3.31-5.40) and 4.87  
(3.65-7.15) per 100 ml/min in women with a history of normal 
pregnancies, preeclampsia and gestational hypertension, respectively 
(p=n.s.). After ischaemia, an increase in FBF was observed in each 
group (p<0.001) with a peak in the initial 30 s after occlusion of about 
250% followed by a slow correction over subsequent 2 min (figure 1). 
There was no difference in FBF response to venous occlusion among 
the three groups. 
Table 4: Plasma aldosterone and renin concentrations before and after tilt testing 
in women with a history of normal pregnancy, preeclampsia and gestational 
hypertension.
N (n=22) PE (n=20) GH (n=10)
Aldosterone basal (pmol/l) 173 (137-310) 191 (152-244) 167 (119-267)
Aldosterone after tilt testing 
(pmol/l)
165 (126-239)# 146 (122-212)# 225 (133-278)
Renin basal (mU/l) 8.1 (7.1-12.4) 8.1 (6.4-14.9) 7.8 (6.1-8.7)
Renin after tilt testing (mU/l) 9.8 (7.3-13.1)# 8.9 (5.7-16.0) 7.5 (5.7-10.6)
N: normal pregnancy, PE: preeclampsia, GH: gestational hypertension
Data presented are median (interquartile range).
# p<0.05 compared with basal levels
Tilt table testing: sympathetic activity and renin-aldosterone 
responses
During tilt testing, there was a rise in MAP and HR (p<0.001) with 
no differences among the three groups (figure 2a and 2b). Baseline 
plasma aldosterone and renin concentration were similar between 
the groups (table 4). In women with a history of normal pregnancy, 
the plasma aldosterone concentration decreased and the renin levels 
increased after tilt testing. This was not observed in women with 
preeclampsia and gestational hypertension, except for a decrease in 
aldosterone in preeclampsia. There were no differences among the 
groups in aldosterone and renin concentration after tilt testing. 
Cold pressor test
MAP and HR increased as a consequence of cold pressor stimulus 
(p<0.001), with no differences among the three groups (figure 3a and 
3b).
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Discussion
This study shows that women who have had preeclampsia or 
 gestational hypertension have greater body mass index, more insulin 
resistance and higher awake and sleep blood pressures, remote from 
their pregnancy than do women who have had normal pregnan-
cies. The observation that preeclampsia and gestational hypertension 
women tended to be heavier and had higher blood pressure (though 
well within the normal range) at the beginning of their pregnancy 
supports the hypothesis that these known cardiovascular risk factors 
(the ‘metabolic syndrome’) are present before the index pregnancy, 
and may be then carried through the pregnancy to increase the risk 
of a hypertensive disorder of pregnancy and in subsequent life to 
contribute to a higher cardiovascular risk. None of the physiological 
stress tests of sympathetic nervous system and endothelial function 
differed among the groups and we found no evidence of renal dys-
function postpartum in this study. Importantly, only three women 
were aware that they had chronic hypertension, yet between 9% and 
29% had hypertension by the gold standard of ABPM criteria. 
Our finding that women with prior preeclampsia or gestational 
hypertension were characterised by higher body mass index, blood 
pressure and relative insulin resistance is relevant as features of the 
metabolic syndrome have been positively associated with hyperten-
sive disorders of pregnancy by several authors.4, 20, 21 A higher blood 
pressure several years after pregnancy has been observed by others in 
women with a history of preeclampsia or gestational hypertension;8, 9, 22 
and this has been confirmed by our study using 24-h ABPM. We have 
also shown the novel finding of elevated sleep blood pressure in these 
women. Using 24-h ABPM, about one in four women with a history 
of gestational hypertension was classified as high blood pressure, in 
contrast to about one in 10 with a history of normal pregnancies. 
Despite demonstrating higher blood pressure and features suggesting 
‘early metabolic syndrome’, we were unable to demonstrate evidence 
of renal dysfunction as reflected by estimated glomerular filtration 
rate or albumin-to-creatinine ratio. We studied women on average 
4-5 years after their pregnancy and it is possible that such changes 
may take longer to develop. On the contrary, others have reported 
an incidence of microalbuminuria of about 30%, 7 years postpartum 
after preeclampsia.23 
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Figure 3: Cold pressor test
a) Change in mean arterial pressure (MAP) during cold pressor test in women with 
a history of normal pregnancy (N, n=19), preeclampsia (PE, n=17) and gestational 
hypertension (GH, n=17).
b) Change in heart rate (HR) during cold pressor test in women with a history of normal 
pregnancy (N, n=19), preeclampsia (PE, n=17) and gestational hypertension (GH, n=17).
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tilt test is an orthostatic challenge test which activates the sympa-
thetic nervous system. Acute standing induces a redistribution of 
blood flow, leading to a decrease in venous return and cardiac output 
which activates the baroreflex system. After the initial hemodynamic 
response, an early phase of stabilization is observed in which blood 
pressure and HR increases under neurovascular control.30 During 
prolonged orthostasis, after about 5 min of standing, humoral mecha-
nisms such as the renin-angiotensin system contribute to maintaining 
blood pressure.30, 31 In our study, the head up table test did show an 
increase in blood pressure and HR in all groups; however, the re-
sponse was similar among groups. 
Tilt testing activated the renin-angiotensin system in controls as re-
flected by an increase in renin levels, although without a subsequent 
rise in aldosterone. During normal pregnancy, plasma renin, aldos-
terone and angiotensin II levels are increased with reduced vascular 
response to angiotensin II; in contrast during preeclampsia, plasma 
renin activity and aldosterone are suppressed, although with higher 
level of aldosterone for the given level of renin.32 During preeclamp-
sia, circulating angiotensin II type 1 autoantibodies are present; those 
antibodies are also detected 18 months post partum in 17% of women 
with previous preeclampsia compared with 3% of women who had 
uncomplicated pregnancy.33 Even though several components of 
the renin-angiotensin system seem to be influenced during PE, our 
study showed no differences among groups in the post partum state 
in women with a history of preeclampsia, gestational hypertension or 
normal pregnancy. 
The cold pressor test has been used in many studies to evaluate 
muscle sympathetic activity.34 The immersion of a limb into ice cold 
water activates pain and temperature fibres. The signal, transmitted 
through the spinothalamic tract, stimulates the sympathetic nervous 
system.30 This response, in contrast to orthostatic stress tests, is not 
mediated by the baroreflex system.34 A study performed early in preg-
nancy (16-20 weeks of gestation) showed an increased blood pres-
sure response to the cold pressor test in women destined to develop 
preeclampsia later in the pregnancy.35 In third trimester pregnancy, 
women with preeclampsia have increased muscle sympathetic nerve 
activity compared with normal pregnant women, when evaluated 
by intraneural microelectrodes.14 We evaluated the cold pressor test 
in women 3-4 years postpartum and observed a similar response 
One of the controversies about the cardiovascular disease risk after 
preeclampsia has been whether the pregnancy itself programs this 
risk or whether the risk factors are brought into pregnancy. The fact 
that insulin resistance can be detected in early pregnancy, before the 
manifestation of preeclampsia or gestational hypertension supports 
the latter.24 In addition, this study gives some further directions to 
this question, showing that a higher blood pressure and body mass 
index were already present in first trimester pregnancy and remain 
this way on average 4 years postpartum. This is in line with a recent 
report, showing that the increased blood pressure and body mass in-
dex in women with a history of preeclampsia or gestational hyperten-
sion can be largely explained by the prepregnancy blood pressure and 
body mass index values.25 Moreover, those women are prone to even 
more weight gain during the decades that follow, when compared 
with women who had normotensive pregnancies.26 In our study of 
less follow up, weight gain from early pregnancy to the study mea-
surement was present to a similar extent in all three groups. Lifestyle 
and dietary habits might contribute to the risk of cardiovascular 
disease. The trend for lower urinary calcium suggests that women 
with a history of preeclampsia or gestational hypertension might have 
a lower dietary calcium intake. Although variations in dietary salt 
intake contribute to the blood pressure observed in a general popula-
tion, our study did not show a difference in urinary sodium excretion 
between groups. 
To measure endothelial function, we used a postocclusion test to 
induce reactive hyperaemia. Similar to a previous report, we found 
no difference in FBF after occlusion measured by strain gauge ple-
thysmography.27 In contrast, others have found reduced vasodilation 
in women with a history of preeclampsia, when using ultrasound 
to determine the changes in vessel diameter after occlusion.10, 12, 22, 28 
Moreover, studies using infusion of vasoactive substances or a mental 
stress test to induce vasodilation also reported impaired FBF respons-
es in women with a history of preeclampsia.11, 29 It is possible that the 
method used to measure endothelial function in our study might not 
have been sensitive enough to detect these differences among groups. 
If so, then true differences are likely to be subtle.  
In our study, no differences in response to two autonomic function 
tests were found between women with either a history of preeclamp-
sia, gestational hypertension or normal pregnancy. The head-up table 
46 47
PA
RT I – Cardiovascular health | Chapter 3 – M
arkers of cardiovascular  disease risk after hypertension in pregnancy
PA
RT I – Cardiovascular health | Chapter 3 – M
arkers of cardiovascular  disease risk after hypertension in pregnancy
References
 
 
 1. Bellamy L, Casas JP, Hingorani AD, Williams DJ. Pre-eclampsia and risk of cardiovascular disease and 
cancer in later life: systematic review and meta-analysis. Bmj. 2007;335:974. 
 
2. Vikse BE, Irgens LM, Leivestad T, Skjaerven R, Iversen BM. Preeclampsia and the risk of end-stage renal 
disease. N Engl J Med. 2008;359:800-9. 
 
3. Irgens HU, Reisaeter L, Irgens LM, Lie RT. Long term mortality of mothers and fathers after pre-eclamp-
sia: population based cohort study. Bmj. 2001;323:1213-7. 
 
4. Rodie VA, Freeman DJ, Sattar N, Greer IA. Pre-eclampsia and cardiovascular disease: metabolic syn-
drome of pregnancy? Atherosclerosis. 2004;175:189-202. 
 
5. Jonsdottir LS, Arngrimsson R, Geirsson RT, Sigvaldason H, Sigfusson N. Death rates from ischemic heart 
disease in women with a history of hypertension in pregnancy. Acta Obstet Gynecol Scand. 1995;74:772-6. 
 
6. Kaaja R, Laivuori H, Laakso M, Tikkanen MJ, Ylikorkala O. Evidence of a state of increased insulin resist-
ance in preeclampsia. Metabolism. 1999;48:892-6. 
 
7. Wolf M, Hubel CA, Lam C, et al. Preeclampsia and future cardiovascular disease: potential role of altered 
angiogenesis and insulin resistance. J Clin Endocrinol Metab. 2004;89:6239-43. 
 
8. Sattar N, Ramsay J, Crawford L, Cheyne H, Greer IA. Classic and novel risk factor parameters in women 
with a history of preeclampsia. Hypertension. 2003;42:39-42. 
 
9. Girouard J, Giguere Y, Moutquin JM, Forest JC. Previous hypertensive disease of pregnancy is associated 
with alterations of markers of insulin resistance. Hypertension. 2007;49:1056-62. 
 
10. Germain AM, Romanik MC, Guerra I, et al. Endothelial dysfunction: a link among preeclampsia, recur-
rent pregnancy loss, and future cardiovascular events? Hypertension. 2007;49:90-5. 
 
11. Agatisa PK, Ness RB, Roberts JM, Costantino JP, Kuller LH, McLaughlin MK. Impairment of endothelial 
function in women with a history of preeclampsia: an indicator of cardiovascular risk. Am J Physiol Heart 
Circ Physiol. 2004;286:H1389-93. 
 
12. Chambers JC, Fusi L, Malik IS, Haskard DO, De Swiet M, Kooner JS. Association of maternal endothelial 
dysfunction with preeclampsia. Jama. 2001;285:1607-12. 
 
13. Joyner MJ, Charkoudian N, Wallin BG. A sympathetic view of the sympathetic nervous system and hu-
man blood pressure regulation. Exp Physiol. 2008;93:715-24. 
 
14. Schobel HP, Fischer T, Heuszer K, Geiger H, Schmieder RE. Preeclampsia -- a state of sympathetic over-
activity. N Engl J Med. 1996;335:1480-5. 
 
15. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis 
of the hypertensive disorders of pregnancy: statement from the International Society for the Study of 
Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy. 2001;20:IX-XIV. 
 
16. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assess 
ment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in 
man. Diabetologia. 1985;28:412-9. 
 
17. Mangos GJ, Walker BR, Kelly JJ, Lawson JA, Webb DJ, Whitworth JA. Cortisol inhibits cholinergic vaso-
dilation in the human forearm. Am J Hypertens. 2000;13:1155-60. 
 
18. Benjamin N, Calver A, Collier J, Robinson B, Vallance P, Webb D. Measuring forearm blood flow and 
interpreting the responses to drugs and mediators. Hypertension. 1995;25:918-23. 
 
19. Silke B, McAuley D. Accuracy and precision of blood pressure determination with the Finapres: an over-
view using re-sampling statistics. J Hum Hypertens. 1998;12:403-9. 
 
of blood pressure and heart rate in women with a history of either 
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ing that any changes in sympathetic nervous system activity during 
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Although it may be that the functional studies above were underpow-
ered to detect subtle differences in autonomic nervous system func-
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In conclusion, women with a history of preeclampsia or gestational 
hypertension have higher awake and sleep blood pressure, body mass 
index and relative insulin resistance compared with women with 
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this study, we found no evidence for postpartum renal dysfunction, 
endothelial dysfunction or sympathetic overactivity. It is important 
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are subtle and that few, if any, women with a history of preeclampsia 
or gestational hypertension will have results in the clearly abnormal 
range. Therefore the strong clinical message is to consider all women 
with prior preeclampsia or gestational hypertension to carry cardio-
vascular risk and adopt healthy lifestyle measures accordingly with 
regular medical follow up.
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Introduction
Preeclampsia affects about 5-8% of all first pregnancies and is a major 
cause of maternal and fetal morbidity and mortality worldwide.1 
Although the symptoms of preeclampsia typically regress within a 
few days post partum, women with a history of preeclampsia have a 
2- to 4-fold higher risk of developing chronic hypertension, stroke, 
venous thromboembolism and ischemic heart disease later in life.2
The predisposition to later cardiovascular disease in women with a 
history of preeclampsia is most likely explained by shared cardiovas-
cular risk factors, such as hypertension, obesity, insulin resistance, 
hyperlipidemia and chronic low grade inflammation.3-5 As a matter 
of fact, endothelial dysfunction plays a central role in the etiology of 
both preeclampsia and cardiovascular disease.6, 7 Moreover, impaired 
vascular dilatation is still present several years after preeclampsia,8-10 
suggesting persistent endothelial dysfunction, which may contribute 
to the development of cardiovascular disease in these women. 
We hypothesized that women with a history of preeclampsia have a 
chronically impaired microvascular function. Therefore, the aim of 
our study was to investigate microvascular reactivity 23 years after 
pregnancy in women with a history of preeclampsia, using similar ob-
servations in women who had uneventful pregnancies only as a refe-
rence. We tested microvascular reactivity by Laser Doppler flowmetry 
of the finger skin during post-occlusive reactive hyperemia (PORH) 
and its relationship with several cardiovascular risk factors.  
Methods
From January 2001 to July 2008, 22 formerly preeclamptic women 
(PE) and 29 parous controls (CON) enrolled in this study. All par-
ticipants were Caucasian and delivered their first child in the pe-
riod between 1979 and 1987 at the Department of Obstetrics of the 
University Hospital of Maastricht, the Netherlands. The primiparous 
subjects were matched for age, BMI and date of delivery. We excluded 
women with preexistent hypertension, diabetes mellitus, renal di-
sease, current cancer therapy or chronic use of corticosteroid medi-
cation. The selection procedure is described in detail elsewhere.11 
Preeclampsia was defined according to the criteria of the Report 
of the National High Blood Pressure Education Program Working 
Group in High Blood Pressure in Pregnancy.1 An uneventful preg-
nancy was defined as a term singleton pregnancy without complica-
tions, such as fetal growth restriction, pregnancy-induced hyperten-
Abstract
Preeclampsia, an endothelial disorder of pregnancy, is associated 
with an increased risk on cardiovascular diseases. Cardiovascular risk 
factors may mediate vascular dysfunction both during pregnancy but 
also later in life. This study aims to investigate microvascular reacti-
vity, and its relationship with several cardiovascular risk factors, in 
women with a history of preeclampsia and controls. In this cross-
sectional study we compared women with a history of preeclampsia 
(PE, n=22) with women with uneventful pregnancies only (CON, 
n=29) 23 years after their first delivery. Participants were matched 
for BMI, age and date of delivery. We assessed blood concentrations 
of fasting glucose, HbA1c, insulin, (total, HDL-, LDL-) cholesterol, 
triglycerides and CRP. Endothelial function was assessed by measure-
ment of skin microcirculatory blood flow by Laser Doppler flowme-
try at the dorsal and ventral site of the finger during post-occlusive 
reactive hyperemia (PORH). PE had higher fasting insulin levels and 
HOMA-IR compared with CON. The PORH response was similar 
in both groups. The area under the curve of PORH correlated with 
insulin and HOMA-IR at both sites, with BMI, triglycerides at the 
dorsal site and with CRP at the ventral site of the finger in PE and not 
in CON. In conclusion, 23 years after pregnancy we did not observe a 
difference in the microvascular hyperemic response between women 
with a history of preeclampsia and controls. Meanwhile, the results of 
our study suggest that insulin resistance and other cardiovascular risk 
factors are related to microvascular reactivity in middle-aged women 
with a history of preeclampsia.
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the difference between maximum blood flow and the baseline value. 
The ratio max/basal was calculated by the maximum flow divided by 
the mean basal flow. To determine the AUC-total we used the period 
between the start of hyperemia and either the return of the signal to a 
(new) baseline, or else, until 6 minutes afterwards. The AUC-1min was 
calculated during the first minute of hyperemia. 
Laboratory measurements 
Fasting triglycerides, total cholesterol, HDL-cholesterol, glucose and 
CRP were measured by standard automated laboratory techniques 
(Beckman Coulter LX20 PRO, Fullerton, USA). LDL-cholesterol was 
calculated by the Friedewald equation. Plasma insulin concentrations 
were measured using AutoDelfia time-resolved fluoroimmunoassay. 
Hyperinsulinemia was considered when plasma insulin levels were 
equal to or above 15 mU/l. We estimated insulin resistance based on 
the homeostasis model assessment of insulin resistance (HOMA-IR), 
using the following formula: HOMA-IR = [fasting serum insulin 
(mU/l) × fasting plasma glucose (mmol/l] / 22.5.14
Statistical analysis
Data are presented as mean with standard deviation (SD) or median 
with interquartile range (IQR), unless otherwise specified. Skewed data 
(insulin, HOMA-IR, AUC) were transformed by square-root transfor-
mation. Differences between groups were tested using Student’s t-test 
or Mann-Whitney U-test. To explore the association between variables 
we used Pearson’s correlation or Spearman’s rank correlation where 
appropriate. Multiple regression analysis was used to adjust for possible 
confounders. A p-value less 0.05 was considered statistically significant.
AUC 
Biological zero 
Mean basal ow 
Time hyperemia 
Time max 
Max ow 
Absolute zero 
Figure 1: Determinants of the post-occlusion reactive hyperemia (PORH) response.
sion or gestational diabetes. The study protocol was approved by the 
hospital ethical committee board and all participants gave written 
informed consent. 
Measurements were performed in the follicular phase (day 5±2) 
of the menstrual period or randomly, when postmeno pausal. 
Antihypertensive drugs were discontinued two weeks prior to the 
measurements. None of the participants were using cholesterol-
lowering medication. Participants did not drink caffeine- or alcohol-
containing beverages and refrained from smoking and eating for at 
least 10 hours before the measurements. The measurements were 
performed in a temperature-controlled room (23-24 oC) with the par-
ticipant lying on a comfortable bed in supine position. We collected 
fasting blood samples for the measurement of several cardiovascular 
risk factors. After an acclimatization period of 30 minutes arterial 
blood pressure was recorded using a semi-automatic oscillometric de-
vice (Dinamap Vital Signs Monitor 1846, Critikon, Tampa, FL, USA). 
Thereafter, on the opposite arm, basal finger skin blood flow was 
measured for 3 minutes using laser Doppler flowmetry. Next, arterial 
occlusion was applied for 5 minutes with a pediatric cuff around the 
wrist inflated to a pressure of 200 mmHg. The post-occlusive reactive 
hyperemia (PORH) blood flow response following deflation of the 
cuff, was recorded during 6 minutes. Vascular reactivity as measured 
by the PORH response reflects endothelial function.12 
Skin microcirculatory blood flow
Skin microcirculatory blood flow was measured by laser Doppler 
flowmetry (FloLAB, Moor Instruments, United Kingdom) on the dorsal 
side of the middle phalanx and the ventral side of the distal phalanx of 
the third finger on the left hand. This non-invasive method measures 
skin blood flow by infrared laser light with a wavelength of 780 nm. 
This light is reflected by skin tissue and scattered by moving red blood 
cells. Flux values are expressed as arbitrary perfusion units (PU). The 
laser light penetrates the skin to a depth of 1.0 mm. The laser Doppler 
flux represents mostly thermoregulatory perfusion.13 All measurements 
were digitalized and analyzed off-line. Biological zero values, obtained 
during arterial occlusion, were subtracted from all flow values. Mean 
basal flow was determined as the mean flow during the last minute 
in rest. Maximum flow, time to maximum, period of hyperemia and 
the area under the curve (AUC) provided the information needed to 
quantify the PORH response (figure 1). Maximum flow was defined as 
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Results
Table 1 lists the characteristics of the study population. Median 
follow-up time since preeclampsia or uneventful pregnancy was 23 
years. Both groups were comparable with respect to age, BMI and 
family history of preeclampsia and hypertension. Although at the 
time of measurements, the women in PE tended to smoke less often 
than those in CON (14 vs. 35%), a larger fraction of the women in 
PE was former smoker. At the time of measurement 8 (36%) PE and 
5 (17%) CON were postmenopausal. Eleven (50%) PE had chronic 
hypertension compared with none in the control group.  
Table 2 lists the clinical variables measured in PE and CON. PE dif-
fered from CON by higher mean values for blood pressure, fasting 
insulin and HOMA-IR, and a higher incidence of hyperinsulinemia 
(23% vs. 0%, p <0.01). Both groups were comparable with respect to 
fasting glucose, total -, HDL- and LDL-cholesterol, triglycerides and 
CRP.
 
Table 3: Post-occlusion reactive hyperemia (PORH) measured by Laser Doppler 
flowmetry in the finger in formerly preeclamptic women (PE) and controls 
(CON).
PE (n=22) CON (n=29) p-value
   Dorsal site
Mean basal flow (PU) 21 (7-46) 16 (6-42) 0.91
Max flow (PU) 81 (66-112) 84  (69-139) 0.51
Ratio max/basal 4.6 (2.4-12.8) 5.8 (2.2-11.8) 0.87
Time hyperemia (s) 156 (122-209) 149 (95-192) 0.25
Time max (s) 16 (10-20) 15 (12-21) 0.72
AUC-total (PU) 7778 (3910-10259) 5523 (3395-9546) 0.28
AUC-1min (PU) 3736 (2533-4953) 3435 (2557-5328) 0.83
   Ventral site
Mean basal flow (PU) 102 (34-192) 87 (33-204) 0.99
Max flow (PU) 230 (172-273) 252 (195-328) 0.28
Ratio max/basal 2.9 (0.9-7.3) 4.1 (1.2-8.9) 0.52
Time hyperemia (s) 196 (150-257) 185 (109-268) 0.49
Time max (s) 34 (14-58) 39 (16-71) 0.41
AUC-total (PU) 28493 (15192-37518) 26615 (15985-52401) 0.69
AUC-1min (PU) 9585 (6917-12458) 10135 (6761-13962) 0.52
Max: maximum, AUC: area under the curve, PU: perfusion units, min: minute. 
Table 1: Characteristics of the study population 
PE (n=22) CON (n=29) p-value
Age (years) 49.0 ± 3.9 49.8 ± 3.9 0.48
BMI (kg/m2) 25.0 ± 3.6 25.5 ± 3.5 0.63
Postmenopausal, n(%) 8 (36) 5 (17) 0.12
Smoking, n(%)
    Current
    Former
    Never
3  (14)
14 (64) 
5 (23)
10 (35)
8 (28)
11 (38)
0.09
0.01
0.25
Chronic hypertension, n(%) 11 (50) 0 (0) <0.01
Stroke, n(%) 2  (9) 1 (3) 0.40
Thrombosis, n(%) 3  (13) 1 (3) 0.18
Family history of, n(%)
    Hypertension, 1st degree
    PE
10 (63)
3 (19)
13 (48)
1 (4)
0.36
0.09
Index pregnancy
GA at birth (weeks)a 34 6/7 (27-43) 40 4/7 (38-42) <0.01
Birth weight (g)a 1801 (880-3350) 3574 (2730-4500) <0.01
Early-onset PE, n(%) 9 (41) -
Recurrent PE, n(%) 5 (23) -
Follow-up time (years)a 23 (20-28) 23 (20-28) 0.12
PE: preeclampsia, CON: controls, BMI: body mass index, GA: gestational age. 
a Data are presented as mean (min-max)
Table 2: Clinical variables measured in formerly preeclamptic women (PE) and 
controls (CON).
PE (n=22) CON (n=29) p-value
Systolic BP (mmHg) 132 ± 17 117 ± 15 <0.01
Diastolic BP (mmHg) 80 ± 12 72 ± 9 <0.01
MAP (mmHg) 100 ± 12 88 ± 10 <0.01
Glucose (mmol/l) 5.0 ± 0.4 5.0 ± 0.4 0.65
HbA1c (%) 5.6 ± 0.4 5.6 ± 0.3 0.70
Insulin (mU/l) 8.3 (6.8-14.0) 6.4 (4.3-9.8) 0.02
HOMA-IR  2.0 (1.6-3.2) 1.4 (1.0-2.3) 0.01
Total cholesterol (mmol/l) 5.94 ± 0.95 5.59 ± 1.02 0.22
HDL-cholesterol (mmol/l) 1.49 ± 0.47 1.48 ± 0.38 0.95
LDL-cholesterol (mmol/l) 3.81 ± 0.69 3.68 ± 0.89 0.54
Triglycerides (mmol/l) 1.33 ± 0.81 1.00 ± 0.42 0.06
CRP (mg/l) 1.5 (1.0-2.3) 1.5 (1.0-2.5) 0.88
BP: blood pressure, MAP: mean arterial pressure, HbA1c: glycosylated hemoglobin 
type A1c, HOMA-IR: homeostasis model assessment of insulin resistance, HDL: high 
density lipoprotein, LDL: low density lipoprotein, CRP: C-reactive protein.
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Figures 1 and 2 illustrate that in PE, but not in CON, AUC-total 
correlated inversely with HOMA-IR both at the dorsal (b=-38.8, 
p=0.009) and the ventral side (b=-47.9, p=0.039) of the finger. The 
latter relationship, in the PE subgroup, persisted after adjustment 
for chronic hypertension, postmenopausal state and smoking in a 
multiple regression analysis (b=-41.2, p=0.013 and b=-55.4, p=0.029, 
respectively). 
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Figure 2: Correlation between the area under the curve (AUC-total) and HOMA-IR 
at the dorsal (a) and ventral (b) site of the finger in formerly preeclamptic women 
(PE) and controls (CON).
Table 3 shows that the PORH response was comparable in PE and 
CON. No differences between groups were found for the maximum 
flow, time to maximum and period of hyperemia. The AUC-total 
tended to be higher and the ratio max/basal to be lower in PE com-
pared with CON, although this was not significant. Three control 
women did not exhibit a post-occlusion response at the ventral side 
of the finger, possibly due to an incorrect position of the ventral 
probe. They had the same characteristics as the whole population and 
were not included in the data-analysis of the ventral PORH response. 
In a univariate analysis (table 4) we tested the correlation between 
the AUC-total and several cardiovascular risk factors. In CON, the 
AUC did not correlate with any of the risk factors. In contrast, in PE, 
the AUC correlated with plasma insulin and HOMA-IR at both sites, 
with triglycerides and BMI at the dorsal, and with CRP at the ventral 
site of the finger. 
Table 4: Univariate correlation between several clinical variables and AUC-total 
on the dorsal and ventral site of the finger in formerly preeclamptic women (PE) 
and controls (CON). 
PE (n=22) CON (n=29)
r p-value r p-value
AUC dorsal
BMI (kg/m2) -0.49 0.02 -0.08 0.67
MAP (mmHg) -0.22 0.32 0.15 0.45
Insulin (mU/l) -0.55 <0.01 0.03 0.88
HOMA-IR  -0.56 <0.01 -0.06 0.78
HDL-cholesterol (mmol/l) 0.29 0.19 0.23 0.24
Triglycerides (mmol/l) -0.43 0.04 0.14 0.47
CRP (mg/l) -0.36 0.10 0.01 0.97
AUC ventral
BMI (kg/m2) -0.42 0.05 -0.14 0.50
MAP (mmHg) -0.04 0.85 -0.07 0.74
Insulin (mU/l) -0.43 0.05 -0.06 0.76
HOMA-IR  -0.45 0.04 -0.07 0.73
HDL-cholesterol (mmol/l) 0.29 0.18 0.02 0.91
Triglycerides (mmol/l) -0.32 0.15 0.30 0.14
CRP (mg/l) -0.48 0.03 0.13 0.53
AUC: area under the curve, r: correlation coefficient, BMI: body mass index, MAP: 
mean arterial pressure, HOMA-IR: homeostasis model assessment of insulin resist-
ance, HDL: high density lipoprotein, CRP: C-reactive protein. 
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We observed a relationship between insulin resistance and the 
micro vascular PORH response. Insulin resistance has been shown to 
correlate with impaired microvascular function in subjects with mild 
hypertension or a family history of diabetes.18-20 Physiologically, acute 
exposure of a microvascular bed to insulin triggers vasodilatation by 
stimulating the endothelial release of nitric oxide.21 This vasodilator 
effect of insulin is important for the regulation of blood flow in the 
microvessels. On the other hand, insulin resistance is related to im-
paired insulin-mediated nitric oxide release.22, 23 For example, healthy 
obese women differ from women with a normal weight by an im-
paired microvascular vasodilator response to directly administrated 
insulin.24 
In our study, the hyperemic response of the skin microvasculature 
correlated inversely with insulin resistance in formerly preeclamp-
tic women only and not in controls. Similarly, others showed an 
impaired vasodilator response in relation to insulin resistance in 
brachial artery of women with a history of preeclampsia and not in 
controls.25 These observations suggest that this relationship observed 
in our study is not confined to the small arterioles, but applies to the 
conductance vessels as well. Apparently, already a marginally raised 
HOMA-IR, as observed in our PE subgroup, is associated with re-
duced microvascular reactivity.  
Possibly, the presence of hypertension may have contributed to 
the observed negative effect of insulin resistance on the microvas-
cular vasodilator response, as half of the women in our PE group 
had chronic hypertension. However, adjustment for the presence 
of chronic hypertension in a multivariate analysis did not modify 
this relationship. The antihypertensive drugs were discontinued two 
weeks prior to measurement, which may have been too short to com-
pletely eliminate the pharmacologic effect, however, this may have 
only attenuated the observed correlations. 
To sum up, women with a history of preeclampsia are at increased 
risk of cardiovascular disease. It is generally thought that endothe-
lial dysfunction precedes the onset of overt cardiovascular disease.26 
Endothelial dysfunction - considered to be responsible for most clini-
cal symptoms during preeclampsia - has been reported to persist post 
partum, even though the disorder seems completely resolved. In this 
study we did not observe a difference in the microvascular hyperemic 
Discussion
The microvascular hyperemic response did not differ between women 
with a history of preeclampsia and controls. Notably, this vasodilator 
response did correlate with several cardiovascular risk factors in the 
group of formerly pre eclamptic women. This suggests that classical 
cardiovascular risk factors are associated with reduced microvascular 
reactivity in women with a history of preeclampsia.
Endothelial function can be investigated by measuring the response 
of a vascular bed to pharmacological or physiological stimuli.15 
Several studies focused on large vessel reactivity in women with a 
history of preeclampsia and observed an attenuated vasodilatory 
response measured by flow-mediated dilatation or venous occlusion 
plethysmography.8, 9, 16 Just one study evaluated microvascular func-
tion several years after preeclampsia, observing a lower response to 
both endothelium-dependent and independent vasodilatation using 
laser Doppler imaging of the forearm 20 years after preeclampsia.10 
In contrast, in our study we did not observe a difference in micro-
circulatory blood flow between PE and controls. To obtain a vasodi-
latory response we did not use a strong pharmacological stimulus, 
but used a post-occlusion test instead to induce hyperemia, which 
may have been less sensitive. The PORH response is mediated by 
both  endothelium-dependent and independent vasodilatation. This 
mixed response may not have been able to discriminate between both 
groups. 
Our study confirms that classical cardiovascular risk factors, such as 
BMI, triglycerides and CRP correlate with the PORH response in the 
group of women with a history of preeclampsia. A large prospective 
cohort study in healthy females showed that the presence of cardio-
vascular risk factors coincides with impaired postischemic skin reac-
tive hyperemia.12 Moreover, the number of cardiovascular risk factors 
can be related to the degree of vascular impairment.12, 17 We hypo-
thesized that middle-aged women with a history of preeclampsia have 
a chronically impaired microvascular function due to persistence of 
endothelial dysfunction. However, we do realize that in this cross-
sectional study we measured women about 23 years after pregnancy 
and several unidentified confounders may have influenced endothe-
lial health in both groups. Another limitation of this study is that we 
had no complete data on the clinical management of these women 
throughout their pregnancies. 
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response between women with a history of preeclampsia and con-
trols 23 years after pregnancy. However, this study did reveal that in a 
group of middle-aged women with a history of preeclampsia, classical 
cardiovascular risk factors correlate closely with the microvascular 
vasodilator response to arterial occlusion. This effect is not observed 
in control women with uncomplicated pregnancies. In conclusion, 
the results of our study provide evidence for the concept that insu-
lin resistance and other cardiovascular risk factors are associated 
with reduced microvascular reactivity in women with a history of 
preeclampsia.
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Abstract
 
Preeclampsia is associated with later kidney disease. This study tested 
the hypothesis that the normal decline in renal function with age is 
more rapid in formerly preeclamptic women than in controls. Four 
groups were compared cross-sectionally; young women with a history 
of preeclampsia (n=34), young controls (n=12), middle-aged women 
with a history of preeclampsia (n=22) and middle-aged controls 
(n=29). We measured blood pressure (semi-automatic device), ef-
fective renal plasma flow (ERPF, para-aminohippurate clearance), 
glomerular filtration rate (GFR, creatinine clearance) and cardiac 
output (Doppler echocardiography). ERPF was lower in both young 
and middle-aged women with a history of preeclampsia relative to 
controls. The decrease in both GFR and ERPF with age was compara-
ble in both groups. In conclusion, the lower renal function in middle-
aged formerly preeclamptic women does not result from accelerated 
age-dependent renal function loss, but from an already reduced renal 
function relative to parous controls at young age. 
Chapter 5
 
Reduced renal function after 
preeclampsia does not result 
from accelerated age-dependent 
renal function loss
Julia Spaan, Timo Ekhart, Marc Spaanderman M, Louis Peeters
Acta Obstetricia et Gynecologica Scandinavica 2010;89:1202-5
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women with a history of preeclampsia (n=34), young controls (n=12), 
middle-aged women with a history of preeclampsia (n=22) and 
middle-aged controls (n=29). 
Since 1996 we have used the same standardized protocol for renal 
studies, described in more detail elsewhere.5, 8 In short,  participants 
used a standardized sodium diet (100 mmol sodium/day) for 1 week 
and refrained from smoking and coffee drinking at least 10 hours 
 prior to the measurements. Antihypertensive drugs were discon-
tinued 2 weeks beforehand. Measurements were performed in the 
mid-follicular phase of the menstrual cycle or randomly when post-
menopausal. All subjects collected a 24-hour urine sample. Blood 
pressure was recorded using a semi-automated device (Dinamap Vital 
Signs Monitor 1846, Critikon, Tampa, FL, USA). Para-aminohippurate 
sodium (PAH, MSD, West Point, PA, USA) was administered using 
a constant-infusion technique. At least 2 hours after the start of the 
infusion we collected blood samples for the measurement of plasma 
levels of PAH. We determined the ERPF from clearance of PAH. 
Effective renal blood flow (ERBF) was obtained by dividing the ERPF 
by (1-hematocrit). RVR was estimated by 80×103 times mean arterial 
pressure (MAP) divided by ERBF. We used creatinine clearance to 
estimate GFR, because inulin was not available owing to manufactural 
problems during the second study period. Doppler echocardiography 
was performed to estimate stroke volume as described previously.8 
Cardiac output (CO) was calculated by multiplying stroke volume by 
heart rate. Total peripheral vascular resistance (TPVR) was calculated 
by 80 times MAP divided by CO. Arterial compliance was estimated 
by stroke volume divided by pulse pressure. 
Statistical analysis
The distribution of data was evaluated by histograms and the 
Kolmogorov-Smirnov test for normality. Groups were compared 
using analysis of variance (ANOVA) followed by Gabriel’s post-hoc 
test for pairwise comparisons. The presence of interaction (group x 
age-category) was tested by linear regression analysis. To estimate the 
effect of group- and age-category on the dependent variable, we used 
multiple linear regression analysis including postmenopausal state 
as a confounder. In this analysis the intercept represents the group 
mean for the reference group (young controls). The effects of group- 
and age-category in percent are derived from the β divided by the 
 intercept. A p-value of <.05 was considered significant. 
Introduction
Preeclampsia is a hypertensive disorder of pregnancy, characterized 
by new-onset hypertension and proteinuria. Women with a history of 
preeclampsia have a five-fold higher risk of end-stage renal disease.1 
Probably, preeclampsia is associated with accelerated renal function 
loss with age. However, data on long-term follow-up of renal func-
tion after preeclampsia are scarce.2-4 Recently, we found a 15% lower 
effective renal plasma flow (ERPF) and a 30% higher renal vascular 
resistance (RVR) in women with a history of preeclampsia more than 
20 years ago relative to age-matched parous controls.5 
In preeclampsia, the kidneys display so-called ‘glomerular endothe-
liosis’, a typical histological abnormality consisting of swelling and 
hypertrophy of glomerular endothelial and mesangial cells. This has 
been reported to resolve within 3 months post partum.6  However, 
the presence of microalbuminuria and a reduced renal function se-
veral years after preeclampsia may indicate persistence of glomerular 
injury.2, 3, 5 
A gradual loss of renal function is observed by a decrease in glomeru-
lar filtration rate (GFR) with 1 ml/min/year from 30 years onward 
in the general population, which can be more pronounced in certain 
risk groups.7 The aim of this study was to test the hypothesis that the 
normal decline in renal function with age is more rapid in formerly 
preeclamptic women than in controls. To this end, we compared renal 
function between a group of young and middle-aged formerly pree-
clamptic women and two age-matched parous control groups.
Material and methods
In order to study the effect of age, this cross-sectional study combined 
two previous studies in formerly preeclamptic and control women at 
different time intervals post partum. Thus, part of the data have been 
previously published. One study, performed between 2001 and 2008, 
included women who were studied about 23 years post partum at an 
age ranging from 40 to 60 years.5 The other study, performed between 
1996 and 1999, examined women about 1 year post partum at an age 
ranging from 20 to 40 years.8 For the latter study, we only selected 
those formerly preeclamptic women (n=34) who were normotensive 
at post partum follow up. Preeclampsia was defined as new onset 
hypertension (bloodpressure ≥140/90 mmHg) and proteinuria after 
20 weeks of gestation. The present study involved four groups: young 
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Results
At the time of measurement, eight (36%) formerly preeclamptic women 
and five (17%) controls were postmenopausal and twelve (55%) for-
merly preeclamptic women and two (7%) controls were hypertensive 
in the middle-aged groups. Table 1 lists the general characteristics and 
variables measured. Body mass index did not differ between groups. 
Although young women with a history of preeclampsia and young 
controls were comparable with respect to blood pressure, TPVR and 
arterial compliance, the former had a lower ERPF. Middle-aged for-
merly preeclamptic women differed from both middle-aged controls 
and young formerly preeclamptic women by a higher blood pressure, 
TPVR and RVR; and a lower arterial compliance, ERPF and ERBF. Age-
category had a different effect in women with a history of preeclampsia 
than in controls for MAP, TPVR and arterial compliance (interaction 
p=.049, p<.001 and p=.015, respectively). This interaction was not 
significant for GFR, ERPF, ERBF and RVR (figure 1, interaction p=.958, 
p=.797, p=.740 and p=.157, respectively). Middle-aged women with a 
history of preeclampsia and middle-aged controls had a lower GFR and 
ERPF than their respective young groups. 
Table 2: The effect of group- and age-category on renal function in a multiple 
regression analysis adjusted for postmenopausal state.
Dependent variable Independent variable b Error 95%-CI p-value
GFR CrCl Intercept 117 4 109 – 126
Preeclampsia -11 4 -19 – -2 0.013
Middle-aged -16 5 -25 – -6 <0.001
Postmenopausal -8 6 -21 – 4 0.191
ERPF Intercept 557 18 522 – 592
Preeclampsia -63 18 -98  – -28 0.001
Middle-aged -82 19 -119 – -44 <0.001
Postmenopausal -50 26 -102 – 2 0.057
ERBF Intercept 866 29 809 - 924
Preeclampsia -86 29 -143 – -28 0.004
Middle-aged -82 31 -143 – -20 0.010
Postmenopausal -79 43 -164 – 6 0.069
RVR Intercept 71.6 4.7 62.3 – 80.9
Preeclampsia 19.4 4.7 10.1 – 28.7 <0.001
Middle-aged 22.5 5.0 12.6 – 32.4 <0.001
Postmenopausal 15.6 7.0 1.8  – 29.4 0.027
GFR: glomerular filtration rate based on creatinine clearance (CrCl), ERPF: effective 
renal plasma flow, ERBF: effective renal blood flow, RVR: renal vascular resistance.  
The intercept represents the group mean for young controls.
Table 1: Demographics, cardiovascular and renal function in formerly 
 preeclamptic women and controls. 
Young 
controls
(n=12)
Young 
preeclampsia
(n=34)
Middle-aged 
controls  
(n=29)
Middle-aged 
preeclampsia 
(n=22)
Age at measurement (y) 31.8 ± 2.2 31.0 ± 3.4 49.8 ± 3.9 48.9 ± 3.9
Age at delivery (y) 30.3 ± 2.4 30.2 ± 3.4 27.2 ± 3.8 26.7 ± 3.6
BMI (kg/m2) 22.2 ± 2.7 24.2 ± 4.3 25.5 ± 3.5 25.0 ± 3.6
Sys BP (mmHg) 111 ± 7 117 ± 12 117 ± 15 132 ± 17*†
Dias BP (mmHg) 69 ± 5 71 ± 9 72 ± 9 80 ± 12†
MAP (mmHg) 82 ± 7 84 ± 10 88 ± 10 100 ± 12*†
CO (L/min) 4.8 ± 0.7 5.3 ± 0.7 5.0 ± 0.7 4.8 ± 0.7
TPVR 
(.100 dyne.s/cm5)
14.3 ± 2.3 13.5 ± 2.2 14.6 ± 1.9 17.5 ± 2.5*†
Arterial compliance 
(mL/mmHg)
1.6 ± 0.2 1.6 ± 0.2 1.6 ± 0.3 1.3 ± 0.3*†
GFR CrCl 
(mL/min/1.73m2)
118 ± 19 106 ± 23 100 ± 19† 88 ± 15†
ERPF 
(mL/min/1.73m2)
565 ± 87 491 ± 90* 463 ± 83† 399 ± 61*†
ERBF
(mL/min/1.73m2)
875 ± 139 778 ± 146 768 ± 138 675 ± 103†
RVR 
(.100 dyne.s/cm5/1.73m2)
76.2 ± 14.9 89.4 ± 20.8 94.9 ± 19.5 121.7 ± 27.9*†
BMI, body mass index; Sys BP, systolic blood pressure; Dias BP, diastolic blood pressure; 
MAP, mean arterial pressure; CO, cardiac output; TPVR, total peripheral vascular resist-
ance; GFR, glomerular filtration rate based on creatinine clearance (CrCl); ERPF, effective 
renal plasma flow; ERBF, effective renal blood flow; RVR, renal vascular resistance. 
*p<.05 compared with control group. †p<.05 compared with young group.
Figure 1: Effective renal plasma flow.
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the presence of hypertension did not seem to have accelerated the 
age-dependent decrease in renal function The absence of an anticipa-
ted effect on renal function loss related to the development of hyper-
tension may be due to our cross-sectional study design and may only 
be solidly answerable in a longitudinal study design. Other factors, 
such as insulin resistance or hyperlipidemia, might have influenced 
our data in both groups.  
The lower renal function, observed in both young and middle-aged 
formerly preeclamptic women, may be consistent with either a re-
duced renal function already present before pregnancy or persistence 
of glomerular injury after preeclamptic pregnancy. The observation 
that preeclampsia but not pregnancy-induced hypertension is associ-
ated with later diabetic nephropathy in type 1 diabetes supports the 
latter option.10 Conversely, women with a history of preeclampsia 
may have a reduced renal function throughout their lives due to a 
low initial nephron number. At birth, the number of nephrons varies 
widely (from 250.000 to 2.000.000), and a low nephron number at 
birth, as seen in association with low birth weight, predisposes to 
hypertension later in life.11
In this study, we found a higher TPVR and a lower arterial compli-
ance in middle-aged formerly preeclamptic women exclusively. This 
observation indicates that the systemic vascular stiffness increased 
with age only in formerly preeclamptic women. Vascular stiffness is 
a hallmark of vascular aging and an independent predictor of car-
diovascular disease. Presumably, hypertension and vascular stiffness 
developed secondary to the reduced renal function in formerly pree-
clamptic women.12 
In conclusion, these findings suggest that the lower renal function 
in middle-aged women with a history of preeclampsia does not 
result from accelerated age-dependent renal function loss, but from 
an  already reduced renal function relative to parous controls at 
young age.
Table 2 provides an estimate for the effect of group- and age-category 
on renal function adjusted for postmenopausal state. Compared with 
young controls, the GFR was 9% lower (b= -11, p=.013) when a his-
tory of preeclampsia was present, 14% lower (b= -16, p=.001) when 
women were middle-aged, and 23% lower when both factors were 
present. The presence of a history of preeclampsia lowered ERPF by 
11% (b= -63, p=.001), lowered ERBF by 10% (b= -86, p=.004) and 
raised RVR by 27% (b= 19.4, p<.001). The factor middle-aged low-
ered ERPF by 15% (b= -82, p<.001), lowered ERBF by 9% (b= -82, 
p=.010) and raised RVR by 31% (b= 22.5, p<.001).
Discussion
This study shows that the decline in renal function with age is com-
parable in formerly preeclamptic women and parous controls. In 
formerly preeclamptic women, renal function is lower at young as 
well as at middle-age.
 
The only other study reporting on GFR several years after pree-
clampsia, did not find a difference in creatinine clearance 5 years 
post partum.4 To our knowledge, no previous studies reported on the 
effect of age on renal function after preeclampsia. We do realize that 
our fin dings should be interpreted cautiously. Firstly, we used cross- 
sectional and not longitudinal data in this study, comparing two 
different populations with small participant numbers. Secondly, data 
on medical history obtained more than 20 years after preeclampsia 
are likely to be incomplete, particularly regarding data on postpartum 
blood pressure. Thirdly, during the two periods obstetrical manage-
ment and guidelines have been modified, which may have reduced 
the comparability of the groups. Therefore, it is important to em-
phasize that the results of this study require confirmation in a larger 
population and preferably using a longitudinal study design.
Renal aging leads to a gradual loss of renal function due to glo-
merulosclerosis and, subsequently, a reduction in nephron number.7 
Several diseases, such as hypertension and diabetes, can aggravate 
glomerulosclerosis and the associated loss of renal function.7 By 
contrast, about one third of normal healthy subjects were found to 
have no decrease in renal function at all with age.9 Our study provides 
indirect evidence for a comparable effect of aging on renal function 
in formerly preeclamptic and control women. Although about half of 
the formerly preeclamptic women were hypertensive at middle-age, 
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Introduction
Preeclampsia, a hypertensive disorder of pregnancy, predisposes to 
premature cardiovascular and renal disease.1, 2 The risk of developing 
end-stage renal disease is 3 times higher in women with a history of 
one preeclamptic pregnancy and 6 to 15 times higher in women with 
a history of recurrent preeclampsia.3 Microalbuminuria, an impor-
tant risk marker for cardiovascular disease,4, 5 is present in about 30% 
of the women with a history of preeclampsia approximately 5 years 
postpartum,6 a figure comparable to the prevalence observed in type 
1 diabetes.7 
It is still unclear whether renal disease in women with a history 
of preeclampsia is pre-existent, induced directly by preeclampsia 
or evolves later, secondary to aging or hypertension. Histological 
findings suggest that the glomerular endotheliosis of preeclampsia 
resolves shortly postpartum, in concert with rapid improvement of 
the glomerular filtration capacity.8, 9 However, long term follow-up 
data on renal function after preeclampsia are scarce and show con-
flicting results. A few studies evaluating kidney function 3-6 years 
postpartum indicated no difference in creatinine clearance between 
women with a history of preeclampsia and controls.8, 10, 11 In contrast, 
we previously found evidence for a lower creatinine clearance, lower 
renal blood flow and higher renal vascular resistance 23 years post-
partum comparing women with a history of preeclampsia and parous 
controls.12 Therefore, the aim of this study is to evaluate renal func-
tion longitudinally over a 14 years period in women with a history of 
preeclampsia and parous controls.   
Methods
In this explorative longitudinal pilot study we measured renal func-
tion in women with a history of preeclampsia and parous controls 
approximately 1 and 14 years postpartum. Women who participated 
in a previous study on renal function in the period between 1996 
and 1999 were invited to participate in this follow-up study.13 At that 
time, women with a history of preeclampsia were recruited at the 
outpatient clinic at postpartum follow-up. Most of them experienced 
a severe form of preeclampsia, either early-onset preeclampsia (<34 
weeks of gestation) or preeclampsia complicated by fetal growth 
restriction or fetal demise. Controls were recruited by advertisement. 
Women with pre-existing renal disease or pre-existing hypertension 
(before pregnancy) were excluded (n=6). We invited 33 women with 
Abstract
Background: Women with a history of preeclampsia are at increased 
risk to develop end-stage renal disease. In this longitudinal study, we 
evaluated renal function in women with a history of severe pree-
clampsia and parous controls over a period of 14 years. 
Methods: Renal function was measured 1 and again14 years postpar-
tum by para-aminohippurate and inulin clearances in 20 women with 
a history of severe preeclampsia and 8 parous controls. 
Results: The difference in glomerular filtration rate 1 year postpartum 
between women with a history of preeclampsia and parous controls 
(112 ± 10 and 125 ± 8 ml/min/1.73 m2, p<.01) had disappeared 
14 years postpartum (104 ± 10 and 109 ± 13 ml/min/1.73 m2, p=.37). 
There was a consistent trend for a lower effective renal plasma flow 
both 1 and 14 years postpartum (477 ± 90 and 543 ± 92, p=.09 and 
473 ± 85 and 543 ± 98 ml/min/1.73 m2, p=.07). 
Conclusion: This explorative study suggests no accelerated renal 
function loss in the first decade after preeclampsia. 
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plasma flow (ERPF) and glomerular filtration rate were corrected for 
body surface area and expressed in ml/min/1.73 m2. Renal vascu-
lar resistance (dyne·s/cm5/1.73 m2) was obtained by dividing mean 
arterial pressure by ERPF/(1-hematocrit). The filtration fraction 
was calculated dividing glomerular filtration rate by ERPF x 100%. 
Participants collected a 24-h urine sample and completeness was 
evaluated by creatinine concentration (at least 6.0 mmol/l if volume 
less than 1000 ml).17 Creatinine clearance was calculated based on 
the timed urine collection. The degree of microalbuminuria was 
evaluated 1 year postpartum by turbidimetry (Cobas Bio centrifugal 
analyzer) and 14 years postpartum by nephelometry (BN ProSpec, 
Siemens Healthcare Diagnostics, Deerfield, IL). The presence of mi-
croalbuminuria was defined as a urinary albumin excretion rate ≥3.5 
g/mol creatinine. All laboratory tests were performed at the time of 
measurement and data were stored in a database. 
Data are presented as mean with standard deviation, unless stated 
otherwise. Differences between groups were examined using the in-
dependent Student’s t-test or Mann-Whitney U-test where applicable. 
Paired differences were tested by the paired t-test. Categorical data 
were tested using Chi-square test. Multivariable analysis was per-
formed using repeated-measures ANOVA. We considered a p-value 
below .05 as statistically significant. To detect a difference between 
groups at 14 years postpartum with respect to glomerular filtration 
rate, based on the available data 1 year postpartum, we needed at 
least 8 women in each group (µ1=125, σ=10, µ2=112, σ=8, α=0.05, 
β=0.8).13
Results
Table 1 shows the characteristics of the study population. Measure-
ments were performed approximately 1 and 14 years  postpartum. 
Groups did not differ with respect to age, BMI and smoking. 
Hypertension was present in 3 (15%) and 7 (35%) women with a 
history of preeclampsia at 1 and 14 years postpartum, respectively. 
All women with hypertension were using antihypertensive drugs. 
The index pregnancy was complicated by early preeclampsia in 65%, 
by fetal demise in 25% and/or by small for gestational age in 25% of 
women with a history of preeclampsia. In almost half of the women 
with a history of preeclampsia (8 out of 17) the subsequent pregnancy 
was complicated by either gestational hypertension or preeclampsia. 
During the period of follow-up, one formerly preeclamptic woman 
a history of preeclampsia and 10 controls to participate once more 
14 years postpartum. No recent address was available from 3 women, 
one woman died as a consequence of pulmonary embolism and one 
woman was currently undergoing treatment with chemotherapeu-
tic drugs. Eight (29%) women with a history of preeclampsia and 
2 (20%) controls declined participation, because of lack of time  
and/or emotional strain. Eventually, 20 women with a history of pree-
clampsia and 8 controls were enrolled in this study. All women gave 
informed consent to participate. The study protocol was approved 
by the Medical Ethical Committee board of Maastricht University 
Medical Center (MEC 08-2-130). 
Preeclampsia was defined as new-onset hypertension (after 20 weeks 
of gestation) accompanied by new-onset proteinuria (≥300 mg/24hr), 
according to the criteria of the International Society for the Study 
of Hypertension in Pregnancy.14 Hypertension was defined as blood 
pressure ≥140 and/or 90 mmHg during the measurement session 
or current use of antihypertensive drugs. We defined early-onset 
preeclampsia as preeclampsia diagnosed before 34 weeks of gesta-
tion. Small for gestational age was defined as a birth weight below the 
5th percentile according to the birth weight reference curves of the 
Perinatal Registry in the Netherlands.15 
Both measurement sessions at 1 and 14 years postpartum were per-
formed by the same research technician using a standardized proto-
col for renal studies, as detailed previously.13 The research technician 
performing the measurements was aware of the clinical diagnosis of 
the participants. All measurements were performed at least 4 months 
postpartum. We standardized the external conditions as much as pos-
sible, with respect to menstrual cycle, medication use and environ-
mental influences. None of the women were breastfeeding or using 
oral contraceptive pills. Antihypertensive drugs were discontinued 2 
weeks before the measurement. 
Arterial blood pressure was measured after an acclimatization period 
of 30 minutes using a semi-automatic oscillometric device (Dinamap 
Vital Signs Monitor 1846, Critikon, Tampa, FL). Renal function was 
derived from the clearances of para-aminohippurate sodium (PAH; 
MSD, West Point, PA) and inulin (first period Inutest, Fresenius 
AG, Bad Homburg, Germany; second period Inutest 25%, Fresenius 
Kabi, Austria) using the constant-infusion technique.16 Effective renal 
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Table 2: Renal function in women with a history of preeclampsia and parous controls. 
Preeclampsia 
(n=20)
Controls 
(n=8)
p-value
MAP 
(mmHg)
1 year postpartum
14 years postpartum
Δ
83 ± 10
94 ± 15
11 (7, 15)*
83 ± 8
91 ± 12
8 (1, 14)*
0.98
0.56
0.38
Serum creatinine 
(µmol/l)
1 year postpartum
14 years postpartum
Δ
70 ± 9
77 ± 9
7 (4, 10)*
64 ± 6
74 ± 13
10 (3, 18)*
0.07
0.45
0.33
Creatinine clearance
(ml/min/1.73 m2)
1 year postpartum
14 years postpartum
Δ
101 ± 20
99 ± 19
-2 (-13, 9)
124 ± 18
104 ± 29
-20 (-44, 4)
<0.05
0.61
0.09
GFR 
(ml/min/1.73 m2)
1 year postpartum
14 years postpartum
Δ
112 ± 10
104 ± 10
-8 (-14, -2)*
125 ± 8
109 ± 13
-16 (-27, -6)*
<0.01
0.37
0.11
ERPF
(ml/min/1.73 m2)
1 year postpartum
14 years postpartum
Δ
477 ± 90
473 ± 85
-4 (-34, 26)
543 ± 92
543 ± 98
0 (-34, 33)
0.09
0.07
0.86
RVR
(.100dyne·s/cm5/1.73 m2)
1 year postpartum
14 years postpartum
Δ
91.7 ± 25.2
99.2 ± 26.5
7.6 (0.6, 14.5)*
79.5 ± 15.9
84.0 ± 18.4
4.5 (-7.5, 16.5)
0.22
0.15
0.63
FF
(%)
1 year postpartum
14 years postpartum
Δ
24.2 ± 4.1
22.6 ± 3.5
-1.6 (-3.1, -0.2)*
24.1 ± 2.2
20.4 ± 2.8
-3.8 (-5.9, -1.5)*
0.99
0.13
0.10
Microalbuminuria
n(%)
1 year postpartum
14 years postpartum
4 (20)
2 (10)
-
-
Data presented are mean ± standard deviation or mean (95% confidence interval),  
unless stated otherwise. MAP: mean arterial pressure, GFR: glomerular filtration  
rate, ERPF:  effective renal plasma flow, ERBF: effective renal blood flow, RVR:  
renal  vascular  resistance, FF: filtration fraction.  
Δ Paired difference, * p<0.05
the magnitude of the rise did not differ statistically between both 
groups. Microalbuminuria persisted at 14 years postpartum in 
2 (10%) out of 4 (20%) women with a history of preeclampsia. 
Figure 1 presents a comparison with reference data from a healthy 
group of potential kidney donors, showing that women with a history 
of preeclampsia have a normal glomerular filtration rate, lower ERPF 
and higher filtration fraction at both time points when compared 
with females of similar age.
Table 1: Characteristics of women with a history of preeclampsia and parous controls. 
Preeclampsia 
(n=20)
Controls  
(n=8)
Follow-up time 
(years)
1 year postpartum
14 years postpartum
1.2 ± 0.8
13.7 ± 1.0
1.8 ± 0.9
14.3 ± 1.0
Age (years) 1 year postpartum
14 years postpartum
31.2 ± 2.6
43.6 ± 2.8
32.7 ± 1.7
45.3 ± 1.8
BMI (kg/m2) 1 year postpartum
14 years postpartum
23.1 ± 4.1
25.6 ± 4.6
21.7 ± 3.0
23.3 ± 3.7
Smoking, n(%) 1 year postpartum
14 years postpartum
2 (10)
1 (5)
1 (13)
3 (38)
Hypertension, 
n(%)
1 year postpartum
14 years postpartum
3 (15)
7 (35)
0 (0)
1 (13)
Parity 1 year postpartum
14 years postpartum
1.0 (1-2)
2.0 (1-4)
1.5 (1-2)
2.5 (2-4)
Index pregnancy GA delivery (weeks) 31 4/7 (27-36)* 39 5/7 (38-42)
Birth weight (g) 1600 (850-2630)* 3360 (2800-3645)
SGA <p5, n(%) 5 (25) 0 (0)
Early preeclampsia, n(%) 13 (65) n/a
Fetal demise, n(%) 5 (25) 0 (0)
Subsequent 
pregnancy 
None
Uncomplicated
Gestational hypertension
Preeclampsia
3
9
4
4
1
7
0
0
Data presented are mean ± standard deviation or median (min-max), unless stated 
otherwise. BMI: body mass index, GA: gestational age, SGA: small for gestational age, 
n/a: not applicable.
* p<0.05 compared with controls
had had an ischemic cardiac event and another a deep venous throm-
bosis. None of the women developed diabetes mellitus during this 
period. All women were premenopausal at the time of the second 
measurement session. 
Table 2 lists the renal function in both groups comparing the mea-
surements 1 and 14 years postpartum. We observed a comparable 
increase over time in mean arterial pressure. One year postpartum, 
the glomerular filtration rate in women with a history of preeclampsia 
was about 10% lower than in controls, a difference that had disap-
peared 14 years postpartum. The glomerular filtration rate decreased 
over time in both groups to a similar extent. The ERPF did not 
change over time, but tended to be consistently lower in women with 
a history of preeclampsia both 1 and 14 years postpartum (p=0.09 
and p=0.07, respectively). The RVR increased over time in women 
with a history of preeclampsia but not in controls; however, 
80 81
 PA
RT II – Renal function | Chapter 6 – Renal function  after  preeclam
psia; a  longitudinal pilot study
 PA
RT II – Renal function | Chapter 6 – Renal function  after  preeclam
psia; a  longitudinal pilot study
In a multivariable sub analysis we studied the effect of follow-up time, 
group and hypertension on renal function. The presence of hyper-
tension related to a higher MAP at 14 years postpartum (interaction 
p=0.02) and a higher RVR and filtration fraction at both time points 
(p<0.01 and p=0.02, respectively) without a significant effect on ERPF 
(p=0.19), ERBF (p=0.11) or GFR (p=0.67).
Discussion
This explorative study gives some directions to the question whether 
women with a history of preeclampsia will have accelerated renal 
function loss in the years after their complicated pregnancy. Most 
importantly, this study showed that the lower renal function at 1 year 
postpartum did not persist or worsen in the first decade ahead. 
Instead, the glomerular filtration rate 14 years postpartum was com-
parable in women with a history of preeclampsia and parous controls. 
Microalbuminuria in women with a history of preeclampsia seemed 
to decrease, rather than to increase in this period. Although these 
data seem reassuring, we did observe a trend for a lower renal blood 
flow in women with a history of preeclampsia that persisted over the 
years. This observation was confirmed when our data were compared 
with a reference group of potential female kidney donors of similar 
age.18 
The strength of this study is the longitudinal design and the accuracy 
of the methods used to assess renal function in a group of women 
with mostly severe preeclampsia and without known pre-existing 
hypertension or kidney disease. The most important limitation of 
our study is the modest size of the control group precluding firm 
conclusions. It may be possible that we observed a relatively higher 
glomerular filtration rate in the controls 1 year postpartum, instead 
of a reduced rate in women with a history of preeclampsia. Actually, 
14 years postpartum the observed values in the controls showed large 
similarities with an external reference group. Another limitation of 
this study is the presence of hypertension as a confounding factor, 
which did influence blood pressure, renal vascular resistance and 
filtration fraction. 
The renovascular profile observed in women with a history of pree-
clampsia (figure 1) of a lower renal blood flow in combination with 
a higher filtration fraction suggests renal hyperfiltration. This com-
pensatory mechanism in the kidneys is a well described phenomenon 
Figure 1: Comparison of renal function in women with a history of  preeclampsia 
1 and 14 years postpartum (black boxes) with reference data from a group of 
 potential female kidney donors of similar age (grey boxes).
Adapted from Berg et al,18 reprinted with permission Nature Publishing Group. 
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in early kidney disease, in which hyperfiltration of the remaining 
nephrons is present.19-21 Our observations show similarities with the 
renovascular profile observed in chronic hypertension of an in-
creased renal vascular resistance, normal glomerular filtration rate, 
reduced renal blood flow and increased filtration fraction.22, 23 This 
altered renovascular profile may already be present before hyperten-
sion becomes clinically evident.22 Whether this profile observed after 
preeclampsia is present independent of hypertension requires further 
investigation. Later in life, due to ageing or after the menopause, it is 
possible that a decline in glomerular filtration rate may become evi-
dent, as suggested by previous observations in women with a history 
of preeclampsia 23 years postpartum.12 
In conclusion, large epidemiological studies have shown that women 
with a history of preeclampsia have an increased risk of develop-
ing end-stage renal disease.3 Although our study does not support 
accelerated renal function loss in the first decade after preeclampsia, 
our data did suggest a possible role for renal hyperfiltration. Larger 
studies are necessary to confirm this. Moreover, functional tests to 
determine the renal reserve capacity by for example a protein load 
may increase our insight in the renovascular function of women with 
a history of preeclampsia.  
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Abstract
 
Women with a history of a hypertensive disorder of pregnancy have 
an increased risk of later cardiovascular disease. Although this offers 
opportunities for primary prevention of cardiovascular disease in 
young women, there appears to be no guidelines or consensus on how 
to screen or treat these women. This review identifies current barriers 
and opportunities for cardiovascular risk management following a 
hypertensive disorder of pregnancy, and suggests a practical approach 
for risk management. 
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to the prevalence of diabetes mellitus at reproductive age, a well ac-
cepted risk marker for cardiovascular disease.9 The prevalence of any 
hypertensive disorder of pregnancy is up to 5-10% of all pregnan-
cies and rising with the epidemic of obesity.8 Women with a history 
of preeclampsia have a doubled risk of stroke, cardiac ischemia or 
venous thrombosis within 10-20 years after pregnancy.10, 11 Moreover, 
they have a four-fold higher risk of chronic hypertension and a 
three-fold higher risk of type 2 diabetes mellitus.10, 12 These comor-
bidities are observed at a relatively young age in mostly premenopau-
sal women. Comparable risk estimates are found in women with a 
history of gestational hypertension only.13-16 The risk of cardiovascular 
disease is further increased in combination with other risk factors of 
the obstetric history, such as preterm birth or fetal growth restriction. 
For example, preterm birth and preeclampsia is associated with an 
8-10 fold higher cardiovascular mortality, instead of a 2 fold higher 
cardiovascular mortality after term preeclampsia compared with term 
normotensive pregnancies.17-19 
Which cardiovascular risk factors are present postpartum?
Risk factors that have been observed postpartum in women who had 
a hypertensive disorder of pregnancy show large overlap with tradi-
tional risk factors for cardiovascular disease. Consistent findings after 
a hypertensive disorder of pregnancy are the presence of an elevated 
blood pressure, body mass index and insulin resistance.20-26 An unfa-
vourable lipid profile is frequently observed postpartum; low HDL-
cholesterol (≤1.29 mmol/l) is present in approximately 40% and high 
triglycerides (≥1.7 mmol/l) in approximately 20% of all women with a 
history of early-onset preeclampsia.27, 28 Although lipid abnormalities 
are frequently present;20, 29, 30 several studies did not find appreciable 
differences compared with women with previous normotensive preg-
nancies.21, 22, 24, 31, 32 A wide range of other cardiovascular risk markers 
have been identified in case-control studies, such as raised circulating 
CRP, TNF-α,VCAM/ICAM, adiponectin, attenuated flow-mediated 
dilatation and increased intima-media thickness.20, 21, 33, 34  
A significant consideration is that several measures in women with a 
history of a hypertensive disorder of pregnancy may still fall within 
a so-called ‘normal’ range. Blood pressure abnormalities may not 
be detectable by routine blood pressure checks but only by use of 
24-hour ambulatory blood pressure measurement; even then these 
blood pressure average levels will still appear to be ‘normal’ though 
 Introduction
Awareness of cardiovascular disease in women is increasing and cur-
rently a main topic of the Heart Associations and Foundations world-
wide. Although several guidelines underscore gender differences in 
clinical presentation, treatment and prognosis, almost no attention is 
given to a unique risk marker in women: the obstetric history. Large 
epidemiological studies have confirmed the association between a 
hypertensive disorder of pregnancy and the risk of future cardiovas-
cular disease. Despite this, physician’s awareness of a hypertensive 
disorder of pregnancy as a risk factor for cardiovascular disease is 
limited. There appears to be no structured follow-up of women after a 
hypertensive disorder of pregnancy and guidelines on cardiovascular 
risk management following a hypertensive disorder of pregnancy are 
lacking. It is time to incorporate this easily identifiable risk marker 
into cardiovascular risk management in women. 
The purpose of this review is to identify current barriers and opportuni-
ties for cardiovascular risk management following a hypertensive disorder 
of pregnancy, and to suggest a practical approach for risk management.
Why does current risk prediction fail in young women?
More women die of cardiovascular disease than of any other cause.1 
During the last decade the focus of primary prevention has widened 
from individuals with the highest risk and largest short-term benefit 
(usually older people with previous cardiovascular events) to in-
clude individuals at an earlier stage of disease to prevent target organ 
damage. Young women have a low absolute risk of cardiovascular 
disease and premenopausal women are in general protected. Few 
women below 65 years of age will be considered high risk with tradi-
tional risk prediction models for cardiovascular disease, such as the 
Framingham risk score, SCORE and QRISK.2-4 Still, women have a 
lifetime risk of cardiovascular disease of 30-40% at 50 years of age.5, 6 
Using a 30-year prediction model, women with multiple risk factors 
(unfavourable lipids, hypertension and smoking) had a 12% predicted 
risk of cardiovascular disease at 25 years of age, increasing to 42% at 
45 years of age.7 The obstetric history offers a unique risk marker to 
identify young women at risk for future cardiovascular disease. 
What is the risk of cardiovascular disease after a hypertensive 
 disorder of pregnancy?
Preeclampsia occurs in 3-5% of all pregnancies;8 a figure  comparable 
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Recently, the latest guideline of the American Heart Association for 
the prevention of cardiovascular disease in women has included a 
hypertensive disorder of pregnancy as a major risk factor for cardio-
vascular disease.1 They recommend postpartum referral by the obste-
trician to a primary care physician or cardiologist, so that in the years 
after pregnancy risk factors can be carefully monitored and controlled 
without further specification. Up until now, it has been clinic- or even 
clinician-dependent whether and how cardiovascular risk assess-
ment is performed after a hypertensive disorder of pregnancy. A few 
clinics have started with postpartum cardiovascular risk counselling 
in a structured manner about 3-6 months postpartum, usually in a 
multidisciplinary setting involving obstetricians, internal medicine 
specialists and cardiologists.38
What are barriers to include the obstetric history in cardiovascular 
risk counselling for women?
Currently, it is unclear whether a hypertensive disorder of pregnancy 
is an independent risk factor for cardiovascular disease or whether 
this is all explained by traditional cardiovascular risk factors. Tools 
are lacking to give an individualised risk estimate of cardiovascular 
disease after a hypertensive disorder of pregnancy. A possible strategy 
is to overcome the latter is to use a classical risk prediction model, 
but to calculate the risk as if the woman was 60 years of age;39 or to 
use a 30-year or lifetime risk prediction model.6, 7 However, this does 
not take the obstetric history into account. Most guidelines will use 
classical risk score models to identify high-risk women that need 
an intervention or treatment. We do not know whether criteria for 
treatment should be more strict for these women, as for those with 
diabetes. Despite these uncertainties (table 1), the least we can do is 
to offer cardiovascular risk management based on existing guidelines 
about cardiovascular risk counselling in asymptomatic people in the 
postpartum period. 
What opportunities does a structured postpartum cardiovascular 
screening program has to offer?
A structured cardiovascular screening program, as proposed in 
table 2, ensures adequate follow-up after a hypertensive disorder of 
pregnancy. It creates a moment to explain and discuss in detail the 
increased risk of cardiovascular disease. Such a screening will identify 
they are higher than in women who had had normal pregnancy.25 
The same holds true for other cardiovascular risk markers. The key 
message is that we need to define what is normal for blood pressure, 
lipids and insulin resistance measures in young women at reproduc-
tive age.
What is the current clinical practice?
The obstetric clinic is often the first clinic where a woman’s blood 
pressure is measured.35 For many years, preeclampsia was considered 
a syndrome of pregnancy that completely resolves after pregnancy 
and women are generally referred back to their general practitioner. 
Nowadays, the risk of cardiovascular disease may be communicated 
to the women at discharge shortly after delivery or at a 6 weeks 
postpartum evaluation at the obstetric outpatient clinic. After that, if 
cardiovascular risk counselling is given later in life, the history of a 
hypertensive disorder of pregnancy is often not taken into account. 
Most guidelines and textbooks on prevention of cardiovascular dis-
ease in women do not mention the obstetric history as a risk factor. In 
a hospital survey, only 5% of all internists asked about preeclampsia 
when taking the medical history of a woman.36 The development of 
chronic hypertension after preeclampsia is frequently not adequately 
monitored; 21 years after preeclampsia about one third of the women 
was hypertensive, but this was only diagnosed in half of them.37 
Table 1: Unanswered questions
 Further research should answer whether a hypertensive disorder of pregnancy is an 
independent risk factor for cardiovascular disease.
There are no tools available to make an individualised risk estimate of cardiovascu-
lar disease that includes the obstetric history.
We do not know the optimal timing and frequency to test for traditional cardiovas-
cular risk markers after a hypertensive disorder of pregnancy. 
 It is unclear whether to use traditional cut-off levels for blood pressure, glucose and 
lipids to define abnormalities or if normal ranges for young women with previous 
normal pregnancies should be developed. 
 The role of screening for additional cardiovascular risk markers or target organ 
damage to predict future cardiovascular disease should be clarified in this specific 
group of women. 
 At present there are no randomised controlled trials in young people unequivo-
cally demonstrating the benefit of antihypertensive or lipid lowering medication on 
cardiovascular disease risk.
 Upcoming trials should prove the efficacy of lifestyle interventions in the reproduc-
tive age on the next pregnancy outcome and long-term cardiovascular health.
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Table 3: Motivational factors for a healthy lifestyle after a hypertensive disorder 
of pregnancy
The hypertensive disorder of pregnancy is a wake-up call.
A healthy lifestyle reduces the risk of future cardiovascular disease. 
A next pregnancy is likely to benefit from a healthy lifestyle as it may reduce the 
recurrence of a hypertensive disorder of pregnancy.
All family members are likely to benefit from a healthy lifestyle, which is particu-
larly important for an infant born premature or small for gestational age.
Motivational factors for a healthy lifestyle
Several factors unique to this specific group of women are present to 
motivate them to adopt a healthy lifestyle (table 3). Group interviews 
revealed that women are more aware of the importance of health after 
a complicated pregnancy and are motivated to adjust their lifestyle.40 
A healthy lifestyle is not only beneficial for their own future health, 
but may also improve the outcome of future pregnancies and the life-
style of her partner and children. This is especially relevant as women 
with a hypertensive disorder of pregnancy give often birth to small 
for gestational age babies, who themselves have a higher risk of later 
cardiovascular disease.41, 42  
Women gain on average 2 kg of weight after each pregnancy and 
this is even more after a hypertensive disorder of pregnancy.43, 44 
Interpregnancy weight gain is associated with a doubled risk of 
gestational hypertension, gestational diabetes or preeclampsia during 
the next pregnancy.45 Therefore, the postpartum period should be an 
important target for weight management and lifestyle counselling.
What is the benefit of a healthy lifestyle?
Lifestyle interventions during reproductive age have potentially a 
large effect on future cardiovascular health. The benefit of a healthy 
lifestyle is evident from large epidemiological studies such as the 
INTERHEART study.46 The adverse effect of hypertension, smok-
ing and diabetes on cardiovascular disease was larger in women 
and young people than in men and elderly people.46-48 In a cohort of 
young women, a favourable cardiovascular risk profile (low blood 
pressure, low cholesterol, non-smoking and non-diabetic) was associ-
ated with 80% lower cardiovascular mortality than in women with 
more than two of these risk factors.49 The lifetime risk of cardiovascu-
lar disease at 50 years of age in women with optimal risk factors was 
only 8%, in contrast to a 50% risk in women with more than 2 risk 
factors based on long-term follow-up of the Framingham cohort.5 
Table 2: Example of cardiovascular risk management following a  hypertensive 
disorder of pregnancy
Time Specialty Measurements Care
6 weeks 
postpartum
Obstetrician Blood pressure •  Counselling about cardiovas-
cular risk.
•  Referral for screening 3-6 
months postpartum.
3-6 months 
postpartum
Multi disci-
plinary team 
preferred
1.  Blood pressure, 
preferably includ-
ing 24-hr ABPM 
or automated 
home blood 
pressure 
2.  Screening for 
metabolic abnor-
malities; body 
mass index, fast-
ing glucose, lipid 
profile 
3.  Dipstick for 
albuminuria and 
proteinuria 
•  Estimate cardiovascular risk 
based on obstetric history 
(gestational hypertension, ges-
tational diabetes, preeclamp-
sia, preterm birth, fetal growth 
restriction) and concomitant 
risk factors (smoking, family 
history, hypertension, meta-
bolic abnormalities).
•  Individualised lifestyle advices 
for all women; family-centred; 
consider local lifestyle inter-
vention programs.
•  Individualised advice about 
next pregnancy; possible 
benefit of a healthy lifestyle on 
recurrence risk.
•  Pharmacological treatment of 
high blood pressure is indi-
cated; treatment of lipid ab-
normalities can be considered.
Referral to 
specialist
1.  In case of signs 
suggestive of 
secondary 
hypertension 
•  Screening for underlying 
secondary hypertension.
2.  In case of persis-
tent albuminuria 
•  Screening for underlying renal 
disease.
Ongoing 
care
General 
practitioner
1.  Yearly weight and 
blood pressure
2.  Every other year 
glucose and 
cholesterol
•  Lifestyle counselling. 
•  Weight management.
ª  Detection of the development 
of chronic hypertension, type 2 
diabetes or dyslipidemias.
women with comorbidities such as hypertension, obesity, type 2 
 diabetes and hyperlipidaemias. Moreover, it allows adequate refer-
ral of  women with signs suggestive of underlying disease, such as 
persistent proteinuria or secondary hypertension. Most importantly, 
it gives the opportunity for primary prevention of cardiovascular 
disease by promoting a healthy lifestyle and offering tailored lifestyle 
interventions.  
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sible benefit of treatment of a high normal blood pressure should first 
be evaluated in clinical research.61 
Lipid lowering treatment
According to the Third Adult Treatment Panel, pharmacologi-
cal treatment is indicated in all women when LDL >4.9 mmol/l, in 
women with 2 or more cardiovascular risk factors when LDL >4.1 
mmol/l, lowering this threshold in women with a 10-year cardiovas-
cular disease risk >10% to LDL >3.4 mmol/l.62 Accordingly, less than 
5% of all women with a history of early-onset preeclampsia will fulfil 
the criteria for lipid lowering medication.28 Meanwhile, the American 
Heart Association recommends treatment of LDL>4.1 mmol/l already 
when only one major cardiovascular risk factor is present, including a 
hypertensive disorder of pregnancy.1 In the general population there 
remains debate about the efficacy of lipid lowering treatment for pri-
mary prevention of cardiovascular disease.63, 64 Hence, more research 
is necessary to decide on which cut-off level to use for treatment in 
this specific group of women. For now, lipid lowering treatment can 
be considered following a hypertensive disorder of pregnancy if one 
of the above criteria are fulfilled. 
Glucose control
About one in seven women will develop type 2 diabetes in the years 
after a hypertensive disorder of pregnancy.65 Pharmacological treat-
ment of overt type 2 diabetes is indicated. However, there is no 
consensus with respect to how prediabetes (impaired fasting glucose 
or glucose intolerance) is to be managed. A recent meta-analysis indi-
cates that lifestyle interventions seem more effective than pharmaco-
logical interventions in preventing diabetes.66   
What about aspirin for stroke prevention?
The Women’s Health Study provided evidence for the efficacy of 
aspirin in the primary prevention of stroke in women, though the 
largest benefit was for women >65 years of age.67 Possible benefits of 
aspirin use should be carefully balanced against the increased risk of 
gastro-intestinal bleeding. Future research should explore the pos-
sible benefit of aspirin for primary prevention in this specific group of 
women.  
What is the effectiveness of postpartum lifestyle interventions?
Several lifestyle intervention trials specifically designed for women 
with a history of a hypertensive disorder of pregnancy are currently 
listed in clinical trial registries. Some preliminary reports indicate 
that women after preeclampsia are willing to participate in such an 
intervention program and will have improved weight, lipid profile 
and vascular function after three months.50, 51 However, in general the 
effectiveness of lifestyle interventions is often disappointing. Even 
in structured programs with frequent contact moments for support, 
the effect on for example weight loss is usually modest and difficult 
to pursue on the long term. Lifestyle interventions in the postpartum 
period failed to show a positive effect in about one third of the trials 
reported in a meta-analysis.52 On the other hand, other lifestyle inter-
ventions have proven to be effective, especially for clinical outcome 
variables such as blood pressure, glucose or lipid control.53, 54 Such 
outcomes can be used as motivational tools to convince and motivate 
women to adhere to their new lifestyle. The potential effect of life-
style change on the next pregnancy is evident from a study in obese 
women that had bariatric surgery as intervention, showing impressive 
reductions in the recurrence of hypertensive disorders in pregnancy.55 
Upcoming research should prove the (cost)effectiveness of postpar-
tum lifestyle interventions in women with a history of a hypertensive 
disorder of pregnancy on the outcome of a subsequent pregnancy and 
long-term cardiovascular health.52 
What are indications for pharmacological treatment?
Blood pressure lowering treatment
One in four women will develop chronic hypertension after a hyper-
tensive disorder of pregnancy.10 Still, there is no consensus about the 
management of hypertension in the immediate postpartum period 
and as a consequence when to discontinue or pursue the adopted 
management.56, 57 Long-term blood pressure lowering aims to re-
duce the risk of cardiovascular disease, but this effect has not been 
unequivocally proven in young people. In the general population, 
systolic blood pressure lowering of 10 mmHg reduces the risk of 
stroke by 40% and of coronary heart disease by 20% in both primary 
and secondary prevention.58 The European Society of Hypertension 
and the Joint National Committee (JNC7) recommend the treatment 
of a blood pressure ≥140/90 mmHg in adolescents.59, 60 In line with 
this, following a hypertensive disorder of pregnancy blood pressure 
lowering treatment is recommended above this threshold. The pos-
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Introduction
Preeclampsia identifies women at risk of cardiovascular disease at 
young age, making them eligible for preventive strategies. The risk of 
ischemic heart disease, thrombosis and stroke is doubled in women 
with a history of preeclampsia.1 The presence of one or more meta-
bolic risk factors, including obesity, hypertension, insulin resistance, 
dyslipidemia and microalbuminuria, is frequently observed post-
partum in women with a history of preeclampsia.2-4 This suggests 
that these women may benefit from life style interventions aimed to 
reduce their risk of cardiovascular disease. However, to our know-
ledge there are no reports supporting a direct correlation between the 
postpartum presence of metabolic risk factors and later cardiovascu-
lar disease in women with a history of preeclampsia. 
Hypertension itself is a major predictor of cardiovascular disease 
in the general population, with an attributable risk to myocardial 
infarction of about 30% in women.5 Chronic hypertension may be an 
important mediator for the development of cardiovascular disease in 
women with a history of preeclampsia. About 25% develops hyper-
tension after preeclampsia in contrast to only 7% after uncomplicated 
pregnancies.1 We postulate that metabolic and obstetric risk factors 
are associated with the development of hypertension after pree-
clampsia. This study aims to identify risk factors that coincide with 
hypertension at postpartum screening and predispose to the develop-
ment of hypertension during a median follow-up period of 6 years in 
a cohort of primiparous women with a history of mainly early-onset 
preeclampsia. 
Material and methods
In Maastricht University Medical Center (MUMC), we routinely 
screen women with a recent history of preeclampsia for underlying 
disorders to increase the efficacy of counseling with respect to a pos-
sible future pregnancy and cardiovascular health. For this study, we 
analyzed the data of all primiparous women with a history of pree-
clampsia (n=683) that have visited this clinic  between 1996 and 2010. 
These women mainly had early-onset preeclampsia (before 37 weeks 
of gestation) or preeclampsia complicated by fetal growth restriction 
or fetal demise. All women were Caucasian and participated at least 
4 months postpartum after they ceased breastfeeding. Oral contracep-
tives were discontinued 4 weeks before the measurement. Exclusion 
criteria were pre-existing hypertension, kidney disease or diabetes 
Abstract
Objective: To identify metabolic and obstetric risk factors associated 
with hypertension after preeclampsia. 
Methods: We analyzed demographic and clinical data from a postpar-
tum screening (blood pressure, micro albuminuria and fasting plasma 
levels of glucose, insulin and lipid profile) from 683 primiparous 
women with a history of preeclampsia. We excluded women with 
pre-existing hypertension, kidney disease or diabetes mellitus. In the 
group of women that were normotensive at postpartum screening, we 
evaluated the risk of developing chronic hypertension in the follow-
ing years using questionnaires.
Results: Hypertension at postpartum screening (n=107, 17% of  
all cases) was related to obesity (OR 1.9, 95% CI 1.1-3.2), elevated 
fasting levels of insulin (OR 1.7, 95% CI 1.0-2.9), low-density  
|lipoprotein (OR 1.6, 95% CI 1.1-2.6), microalbuminuria  
(OR 2.3, 95%-CI 1.3-4.0), family history of hypertension  
(OR 1.8, 95% CI 1.1-2.8) and delivery before 34 weeks of gestation 
(OR 2.5, 95% CI 1.6-4.0). We identified 27 cases of hypertension 
within 2095 person-years during a median 6 year follow-up in the 
group of women normotensive at postpartum screening. The hazard 
rate for the development of hypertension was 2.9 (95% CI 1.2-7.5) 
and 8.1 (95% CI 2.8-22.9), respectively, when 2 and ≥3 components 
of the metabolic syndrome were present; 3.7 (95% CI 1.4-10.0) for 
 family history of hypertension and 4.3 (95% CI 1.6-11.5) for recur-
rence of a hypertensive disorder in pregnancy. 
Conclusion: Several metabolic and obstetric risk factors related to 
hypertension postpartum in the short term and predisposed to the 
subsequent development of chronic hypertension after preeclampsia 
in initially normotensive women. 
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The main outcome measure of this study was hypertension after 
preeclampsia, which was evaluated at postpartum screening and 
during follow-up. We considered women hypertensive at postpar-
tum screening, when automated blood pressures were ≥140 mmHg 
systolic and/or ≥90 mmHg diastolic or when using antihypertensive 
drugs. We evaluated the development of hypertension by a short 
health questionnaire sent out every 2 years to all women who had had 
a diagnostic work-up at least 18 months ago. We used self-reported 
antihypertensive treatment to define hypertension at follow-up. 
Statistical analysis
Data are presented as mean ± standard deviation or median with 
interquartile range. The rate of missing data ranged from 1 to 8%. 
Differences between groups were tested using independent t-test or 
Mann-Whitney U-test. Proportions were compared by chi-square test. 
We used logistic regression analysis to test the association between 
several risk factors and the presence of hypertension at postpartum 
screening. Cox proportional hazard analysis was used to estimate the 
hazard to develop hypertension during follow-up. The event was oc-
currence of hypertension during follow-up (yes/no). Time-to-event 
was calculated by the time elapsed between year of postpartum screen-
ing and the year of initiating antihypertensive drugs (16 events) or,  
No hypertension
n=312 (92%) 
Hypertension
n=27 (8%) 
Primiparous women with a history
of preeclampsia n=683     
Excluded n=57 (8
%)pre-existing disease
hypertension n=40
diabetes mellitus n=5
kidney disease n=12   
Postpartum screening
n=626 
Hypertensive at screening
n=107 (17%) 
Postpartum screening
<18 months ago n=49  
Questionnaire 
n=470 
Responders n=339 (72%)
2095 person-years 
Figure 1: Selection of study population.
mellitus. The Medical Ethical Committee board of MUMC approved 
this study (MEC 0-4-049).
At the postpartum screening we recorded blood pressure for a period 
of 30 minutes using a semi-automatic oscillometric de vice in half-
sitting position (Dinamap Vital Signs Monitor 1846, Critikon, Tampa, 
FL, USA) and median values were used for analysis. Blood was col-
lected for fasting plasma lipid profile, glucose and insulin. We deter-
mined fasting triglycerides, total cholesterol, high-density lipoprotein 
(HDL)-cholesterol and glucose using standard automated labora-
tory techniques (Beckman Coulter LX20 PRO, Fullerton, USA). 
Low-density lipoprotein (LDL)-cholesterol was calculated by the 
Friedewald equation. Plasma insulin concentrations were measured 
using AutoDelfia time-resolved fluoroimmunoassay. We estimated 
insulin resistance based on the homeostasis model assessment  
of insulin resistance (HOMA-IR), using the following formula:  
HOMA-IR = [fasting serum insulin (mU/l) × fasting plasma glucose 
(mmol/l)] / 22.5.6 Microalbuminuria was measured by turbidometry 
(Cobas Bio centrifugal analyzer) and since 2007 by nephelometry 
(BN ProSpec, Siemens Healthcare Diagnostics, Deerfield, IL). 
 
Preeclampsia was defined according to the criteria of the Report 
of the National High Blood Pressure Education Program Working 
Group on High Blood Pressure in Pregnancy.7 Small for gestational 
age was defined as a birth weight below the 10th percentile accor-
ding to the birth weight reference curves of the Perinatal Registry in 
the Netherlands. Family history was evaluated using a standard form 
and for this analysis only first-degree relatives were taken into ac-
count. The metabolic score consisted of components of the metabolic 
syndrome as defined by the Third Adult Treatment Panel (updated 
version) and included, elevated glucose, low HDL-cholesterol and 
elevated triglycerides.8 A high-normal blood pressure was defined 
as a blood pressure of 130-139 mmHg systolic and/or 85-89 mmHg 
diastolic;9 and was only used to predict the development of hyperten-
sion at follow-up. Cut-off values for other metabolic risk factors as to-
tal cholesterol, LDL-cholesterol and microalbuminuria were defined 
according to the criteria of the European Society of Hypertension;9 
for plasma insulin and HOMA-IR we used the 75th percentile in our 
population as cut-off point. 
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Of these women, 339 (72%) responded to at least one questionnaire. 
During a median follow-up of 6 (IQR 4-9, min-max 1-14) years co-
vering 2095 person-years, we identified 27 cases of new-onset hyper-
tension, an incidence of 13 cases per 1000 person-years. Five women 
did develop type 2 diabetes during follow-up. 
Table 1 lists the characteristics and clinical variables of the hyper-
tensive and normotensive women with a history of preeclampsia at 
postpartum screening. The screening was performed about 8 (IQR 
6-18, min-max 4-92) and 10 (IQR 6-19, min-max 4-166) months 
postpartum in the hypertensive and normotensive women, respec-
tively. Groups were comparable with respect to age and smoking. 
Hypertensive women delivered at an earlier gestational age of an in-
fant with a lower birth weight compared with normotensive women. 
A family history of hypertension was more often present and hyper-
tensive women had a higher body mass index (BMI) and elevated 
fasting plasma levels of insulin, total-, LDL-cholesterol and trigly-
cerides compared with normotensive women. Microalbuminuria was 
present in 22% of hypertensive and in 12% of normotensive women 
with a history of preeclampsia (p<0.01). 
Table 2 shows to what extent risk factors at postpartum screening 
coincided with hypertension after adjustment for maternal age, smo-
king and months postpartum, with and without adjustment for BMI. 
The presence of hypertension was associated with obesity 
(OR 1.9, 95%-CI 1.1-3.2), elevated levels of insulin (OR 2.2, 95%-CI 
1.4-3.5) and insulin resistance based on HOMA-IR (OR 1.7, 95%-CI 
1.0-2.7). Adjustment for BMI attenuated the associations with insulin 
and HOMA-IR (OR 1.7, 95%-CI 1.0-2.9 and OR 1.2, 95%-CI 0.7-2.1, 
respectively). Hypertension related to elevated levels of total-  
and LDL-cholesterol and microalbuminuria, independent of  
BMI (OR 1.6, 95%-CI 1.0-2.4; OR 1.6, 95%-CI 1.1-2.6 and  
OR 2.3, 95%-CI 1.3-4.0, respectively). Hypertension was associated 
with a family history of hypertension and delivery before 34 weeks 
of gestation (OR 1.8, 95%-CI 1.1-2.8 and OR 2.5, 95%-CI 1.6-4.0, 
 respectively) and not with the birth of a small for gestational age 
infant. 
Table 1: Characteristics and clinical variables at postpartum screening in 
 primiparous women with a history of preeclampsia (n=626).
Hypertensive
(n=107)
Normotensive
(n=519)
p-
value
Postpartum interval (months) 8 (6-18) 10 (6-19) 0.06
Age (years) 31.4 ± 4.1 30.7 ± 4.3 0.16
Smoking (n,%) 19 (18) 75 (15) 0.39
BMI (kg/m2) 26.5 ± 5.7 25.1 ± 4.6 0.01
Family hypertension (n,%) 69 (66) 266 (52) <0.01
Family cardiovascular disease (n,%) 55 (52) 269 (53) 0.95
GA delivery (weeks) 32 0/7 (29-34) 33 4/7 (30-36) <0.01
Birth weight (g) 1398 (945-1806) 1725 (1090-2450) <0.01
Fetal demise (n, %) 11 (10) 30 (6) 0.22
Glucose (mmol/l) 5.1 ± 0.6 5.1 ± 0.5 0.59
Insulin (mmol/l) 11.0 (7.4-16.0) 9.2 (6.6-13.0) <0.01
HOMA-IR 2.6 (1.6-3.4) 2.1 (1.4-3.1) 0.02
Total-cholesterol (mmol/l) 5.2 ± 1.0 4.8 ± 0.9 <0.01
HDL-cholesterol (mmol/l) 1.4 ± 0.3 1.4 ± 0.9 0.88
LDL-cholesterol (mmol/l) 3.3 ± 0.9 3.1 ± 0.8 <0.01
Triglycerides (mmol/l) 1.01 (0.71-1.30) 0.80 (0.56-1.15) <0.01
Microalbuminuria >3.5 g/mol creat 
(n, %)
22 (22) 58 (12) <0.01
Data are presented as mean ± standard deviation or median (interquartile range), 
unless stated otherwise. BMI, body mass index; HOMA-IR, homeostatic model 
insulin resistance; HDL, high-density lipoprotein; LDL, low-density lipoprotein; creat, 
creatinine.
if not available, the year halfway the most recent follow-up interval 
(11 events). Data were censored for follow-up time if the event had 
not occurred. A following pregnancy was taken into account only 
when delivery preceded the event. As a rule of thumb we defined 
that we needed at least 5 cases for each independent variable in the 
model.10  A p-value below 0.05 was considered statistically significant. 
Results
Figure 1 presents a flowchart of the selection of the study population. 
Exclusion for kidney disease included nine cases of systemic lupus 
erythematosus and one case of atrophic kidney, kidney aplasia and 
Fabry’s syndrome. Of the 626 primiparous women with a history of 
preeclampsia, 107 (17%) were hypertensive and 519 (83%) were nor-
motensive at postpartum screening. A total of 470 women received 
a follow-up questionnaire; they were all normotensive at the time of 
postpartum screening and had had at least 18 months of follow-up. 
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Table 3: Risk factors associated with the development of hypertension during 
a median 6 years follow-up of women with a history of preeclampsia who were 
normotensive at postpartum screening (n=339).
Model 1
HR (95%-CI)
Model 2 
HR (95%-CI)
Metabolic variables
Metabolic score† <2 components
2 components
≥3 components
1.0
2.9 (1.2-7.5)
8.1 (2.8-22.9)
-
-
-
†Obesity ≥30 kg/m2 3.1 (1.3-7.4) -
†Blood pressure 130-139/85-89 mmHg 4.5 (2.0-10.1) 3.8 (1.6-8.8)
†Glucose ≥5.6 mmol/l 1.6 (0.6-4.0) 1.2 (0.4-3.2)
†HDL-cholesterol <1.29 mmol/l 1.9 (0.9-4.2) 1.5 (0.7-3.4)
†Triglycerides ≥1.7 mmol/l 1.0 (0.2-4.2) 0.8 (0.2-3.3)
Total-cholesterol >5.0 mmol/l 1.0 (0.4-2.1) 1.0 (0.4-2.2)
LDL-cholesterol >3.0 mmol/l 1.3 (0.6-2.9) 1.2 (0.6-2.7)
Insulin ≥14 mmol/l 2.2 (1.0-4.9) 1.4 (0.6-3.6)
HOMA-IR ≥ 3.2 1.7 (0.7-3.8) 1.7 (0.7-3.9)
Microalbuminuria ≥3.5 g/mol creat 1.1 (0.3-3.8) 1.3 (0.4-4.4)
Family history
Hypertension 1st degree 4.1 (1.5-10.9) 3.7 (1.4-10.0)
CVD 1st degree 1.8 (0.8-4.2) 1.7 (0.7-4.0)
Obstetric history
SGA ≤ p10 0.9 (0.4-2.3) 1.0 (0.4-2.5)
GA delivery <34 weeks 2.3 (0.9-5.8) 2.0 (0.8-5.1)
Following pregnancy None
Uncomplicated
PE/GH
1.4 (0.4-4.7)
1.0
4.5 (1.7-11.8)
1.3 (0.4-4.3)
1.0
4.3 (1.6-11.5)
27 cases for 2095 person-years.
Model 1: Adjusted for maternal age, smoking and months postpartum.
Model 2: Adjusted for maternal age, smoking, months postpartum, and BMI.
† Components of the metabolic score. HR, hazard ratio; HDL, high-density lipoprotein; 
LDL, low-density lipoprotein; HOMA-IR, homeostatic model insulin resistance; creat, 
creatinine; CVD, cardiovascular disease; SGA, small for gestational age; p10, tenth 
percentile; GA, gestational age; PE, preeclampsia; GH, gestational hypertension.  
LDL-cholesterol, triglycerides and birth of a small for gestational 
age infant were not associated with hypertension during follow-up. 
A family history of hypertension and recurrence of a hypertensive 
disorder in the next pregnancy were independent of BMI related to 
the occurrence of hypertension during follow-up (HR 3.7, 95%-CI 
1.4-10.0 and HR 4.3, 95%-CI 1.6-11.5, respectively). 
Table 2: Risk factors associated with the presence of hypertension at postpartum 
screening in women with a history of preeclampsia (n=626).  
HT 
(n=107)
n(%)
NT 
(n=519)
n(%)
Model 1
OR 
(95%-CI)
Model 2 
OR 
(95%-CI)
Metabolic variables
Metabolic score† <2 components
2 components
≥3 components
78 (76)
17 (17)
8 (8)
402 (83)
67 (14)
24 (5)
1.0
1.3 (0.7-2.3)
1.8 (0.8-4.1)
-
-
-
†Obesity ≥30 kg/m2 23 (21) 67 (13) 1.9 (1.1-3.2) -
†Glucose ≥5.6 mmol/l 16 (16) 73 (15) 1.0 (0.6-1.8) 1.0 (0.6-1.8)
†HDL-cholesterol <1.29 mmol/l 48 (45) 209 (41) 1.3 (0.8-1.9) 1.1 (0.7-1.7)
†Triglycerides ≥1.7 mmol/l 14 (13) 46 (9) 1.6 (0.8-3.0) 1.2 (0.6-2.4)
Total-cholesterol >5.0 mmol/l 52 (49) 186 (36) 1.7 (1.1-2.5) 1.6 (1.0-2.4)
LDL-cholesterol >3.0 mmol/l 65 (62) 239 (47) 1.8 (1.1-2.7) 1.6 (1.1-2.6)
Insulin ≥14 mmol/l 38 (39) 117 (24) 2.2 (1.4-3.5) 1.7 (1.0-2.9)
HOMA-IR ≥ 3.2 32 (33) 113 (24) 1.7 (1.0-2.7) 1.2 (0.7-2.1)
Microalbuminuria ≥3.5 g/mol creat 22 (22) 58 (12) 2.3 (1.3-4.0) 2.3 (1.3-4.0)
Family history
Hypertension 1st degree 69 (66) 266 (52) 1.8 (1.2-2.8) 1.8 (1.1-2.8)
CVD 1st degree 55 (52) 269 (53) 1.0 (0.6-1.5) 1.0 (0.6-1.5)
Obstetric history
SGA ≤ p10 24 (24) 126 (25) 0.9 (0.5-1.4) 0.9 (0.5-1.4)
GA delivery <34 weeks 78 (74) 266 (52) 2.6 (1.6-4.2) 2.5 (1.6-4.0)
Model 1: Adjusted for maternal age, smoking and months postpartum.
Model 2: Adjusted for maternal age, smoking, months postpartum, and BMI.
† Components of the metabolic score. OR, odds ratio; HT, hypertensive; NT, normo-
tensive; HDL, high-density lipoprotein; LDL, low-density lipoprotein; HOMA-IR, 
homeostatic model insulin resistance; creat, creatinine; CVD, cardiovascular disease; 
SGA, small for gestational age; p10, tenth percentile; GA, gestational age. 
Table 3 shows to what extent risk factors at postpartum screening 
were associated with the development of hypertension during a me-
dian follow-up of 6 years after adjustment for maternal age, smoking 
and months postpartum, with and without adjustment for BMI. The 
hazard rate for the presence of 2 and ≥3 components of the meta-
bolic syndrome was 2.9 (95%-CI 1.2-7.5) and 8.1 (95%-CI 2.8-22.9), 
respectively (see figure 2). Obesity and high-normal blood pressure 
predisposed to the development of hypertension (HR 3.1, 95%-CI 
1.3-7.4 and HR 3.8, 95%-CI 1.6-8.8, respectively). Associations of 
HDL-cholesterol and insulin with hypertension during follow-up 
disappeared after adjustment for BMI. Moreover, glucose, total- and 
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postpartum period may still normalize over the years, as 14 out of 
74 women who were hypertensive at postpartum screening (and who 
filled out a questionnaire), did not indicate to use antihypertensive 
medication during follow-up. We used self-reported antihypertensive 
treatment to define hypertension during follow-up, as we intended to 
restrict our outcome to these women that have a confirmed diagnosis of 
hypertension. Self-reported hypertension underestimates the incidence 
of new-onset disease, but is reliable if reported to be present.12, 13 
The prevalence of metabolic abnormalities at postpartum screening 
was high in our study population, which is in line with others.3, 4, 14 
Our study shows that these metabolic risk factors are associated with 
hypertension after preeclampsia. Whether or not the placental disor-
der itself contributes to this risk is still under debate. This study gives 
some direction to this question, suggesting a possible effect of disease 
severity as women with an earlier onset of preeclampsia (delivery be-
fore 34 weeks of gestation) had more often hypertension at postpar-
tum screening. On the other hand, we could not confirm an associa-
tion between small for gestational age and maternal hypertension.
This study gives further support for the current view that lifestyle 
interventions may be beneficial to these women. The benefit of a 
healthy lifestyle is clear from large epidemiological studies,5, 15 but 
there is a strong need for trials proving the (cost)effectiveness of 
postpartum lifestyle interventions on long-term cardiovascular 
disease outcomes, such as stroke and myocardial infarction.16 Some 
preliminary reports suggest that women with a history of preeclamp-
sia are willing to participate in such an intervention program and will 
have improved weight and lipid profile after three months.17, 18 Several 
trials in women with gestational diabetes or obesity suggest that a 
postpartum lifestyle intervention is feasible.19, 20 
We want to emphasize that a high-normal blood pressure was a 
strong predictor for the development of hypertension in the following 
years. Recent evidence shows that there is a continuous relationship 
between blood pressure and cardiovascular disease risk; the cut-off 
level of 140/90 mmHg for hypertension seems arbitrarily.21, 22 Some 
studies suggest that it may be beneficial to treat people with a high-
normal blood pressure, especially if concomitant risk factors are 
present.9, 23, 24 Whether this also applies to women with a history of 
preeclampsia requires further research. 
Discussion
The presence of hypertension at postpartum screening related to 
modifiable risk factors such as obesity, hyperinsulinemia and dyslipi-
demia. The subsequent development of hypertension in women, who 
were normotensive at postpartum screening, was 3 times more likely 
when obesity was present and 4 times more likely when the blood 
pressure at postpartum screening was within the high-normal range. 
The risk of developing hypertension increased even more when 3 or 
more components of the metabolic syndrome were present. These 
findings support the view that women with a history of preeclampsia 
are likely to benefit from life-style interventions to reduce their long-
term cardiovascular disease risk. 
The total prevalence of chronic hypertension after preeclampsia in 
this study of about 25% was comparable to previous reports.1 This is 
higher than the expected prevalence of hypertension in the Dutch 
population of women of reproductive age of about 2.8-5.6%.11 We 
observed a relatively high proportion of hypertension directly at 
postpartum screening (17%) and another 8% developed hyperten-
sion during a median 6 years follow-up. Hypertension in the early 
Follow-up time (years)
97531
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Figure 2: Cumulative hazard of hypertension stratified by metabolic score in women 
with a history of preeclampsia who were normotensive at postpartum screening.
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In conclusion, this study showed that several metabolic risk factors, 
such as obesity, insulin resistance and dyslipidemia, coincided or 
predisposed to hypertension after preeclampsia. Besides, this study 
identified several other clinical variables useful in postpartum cardio-
vascular risk stratification after preeclampsia, such as a family history 
of hypertension, a high-normal blood pressure and recurrence of a 
hypertensive disorder in the next pregnancy.  
Table 4: Comparison of characteristics and clinical variables at postpartum 
screening in non-responders and responders (n=470).
Non-responders
(n=131)
Responders
(n=339)
p-value
Postpartum interval (months) 9 (6-17) 10 (7-20) 0.14
Age (y) 30.3 ± 5.2 31.0 ± 3.8 0.18
Smoking (n,%) 30 (23) 37 (11) <0.01
BMI (kg/m2) 25.3 ± 5.3 24.9 ± 4.4 0.45
Family hypertension (n,%) 72 (56) 170 (51) 0.32
Family cardiovascular disease (n,%) 68 (53) 184 (55) 0.62
GA delivery (wks) 35 0/7 (32-37) 33 0/7 (30-36) <0.01
Birth weight (g) 1856 (1162-2683) 1615 (1013-2319) 0.02
Fetal demise (n, %) 11 (8) 16 (5) 0.13
Glucose (mmol/l) 5.1 ± 0.5 5.1 ± 0.5 0.41
Insulin (mmol/l) 9.3 (5.9-15) 9.4 (6.7-13.0) 0.61
HOMA-IR 2.0 (1.3-3.3) 2.1 (1.5-3.0) 0.53
Total-cholesterol (mmol/l) 4.7 ± 1.0 4.9 ± 0.9 0.16
HDL-cholesterol (mmol/l) 1.3 ± 0.3 1.4 ± 0.3 <0.01
LDL-cholesterol (mmol/l) 3.0 ± 1.0 3.1 ± 0.8 0.59
Triglycerides (mmol/l) 0.83 (0.59-1.20) 0.77 (0.54-1.06) 0.19
Microalbuminuria (>3.5 g/mol creat) 0.9 (0.6-1.7) 0.9 (0.5-1.8) 0.50
Data are presented as mean ± standard deviation or median (interquartile range), 
unless stated otherwise. BMI, body mass index; HOMA-IR, homeostatic model 
insulin resistance; HDL, high density lipoprotein; LDL, low density lipoprotein; creat, 
creatinine.
There are several limitations of our study. Firstly, the study popula-
tion consisted of Caucasian women only and women with mild pree-
clampsia were relatively underrepresented. Moreover, it would have 
been preferably to have a control group of women who had normo-
tensive pregnancies. Secondly, we identified some differences in the 
risk profile of responders and non-responders to the questionnaire. 
A sub-analysis showed that non-responders delivered at a later gesta-
tional age, smoked more often and had a slightly less favorable lipid 
profile, without differences in BMI (table 4). Thirdly, first-trimester 
booking blood pressures of the index pregnancy were unfortunately 
not available. Some women with hypertension at postpartum screen-
ing may have had underlying secondary hypertension instead of 
essential hypertension, which is less likely to be related to metabolic 
risk factors and might have led to an underestimation of association 
estimates. 
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Summary and general discussion
This thesis focuses on the question whether women with a history of 
preeclampsia will have impaired long-term cardiovascular health and 
renal function. Based on findings in this thesis we can conclude that 
several years after preeclampsia women have a higher blood pressure, 
increased vascular resistance, higher body mass index and more often 
insulin resistance compared with parous controls. This profile is often 
referred to as ‘the metabolic syndrome’ and the presence of one or more 
of these constituents increases their risk for chronic hypertension and 
cardiovascular disease. The presence of these modifiable risk factors 
suggests that women may benefit from lifestyle interventions to prevent 
cardiovascular disease. In order to give these women their best possible 
long term outcomes, a standardized cardiovascular risk assessment 
postpartum is recommended after a hypertensive disorder of pregnancy. 
The main findings of each chapter will be summarized below. 
Part I - Cardiovascular health
The first part of this thesis describes the cardiovascular health of 
women with a history of preeclampsia. Chapter 2 describes a group 
of women 23 years postpartum. Half of the women with a history 
of preeclampsia had developed chronic hypertension. Notably, both 
normotensive and hypertensive women had increased (reno)vascu-
lar resistance and reduced renal blood flow compared with parous 
controls. Higher blood pressures were confirmed in chapter 3 by 
24-h ambulatory blood pressure monitoring 4-6 years postpartum. 
This study suggests that a higher BMI and blood pressure may have 
been present already before pregnancy, but provided no evidence for 
differences in creatinine clearance, endothelial dysfunction or sym-
pathetic activity. In chapter 4, we found microvascular function after 
post-occlusion reactive hyperemia to be comparable between women 
with a history of preeclampsia and parous controls. Interestingly, 
insulin resistance did inversely relate to microvascular function only 
in women with a history of preeclampsia.
Part II - Renal function
The second part of this thesis focuses on renal function after pree-
clampsia. We tested the hypothesis that the normal decline in renal 
function with age is more pronounced in women with a history of 
preeclampsia. A comparison between two cross-sectional groups of 
young and middle-aged women in chapter 5 did not support this hy-
pothesis, but suggested that a reduced creatinine clearance and renal 
Chapter 9
General discussion
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risk for cardiovascular disease. Chapter 8 shows that the number of 
constituents of the metabolic syndrome present increases the risk to 
develop chronic hypertension after preeclampsia. 
This does not implicate that women without metabolic risk factors 
are not at risk for cardiovascular disease. It is still unclear whether 
preeclampsia is an independent risk factor for cardiovascular disease. 
Research to explore this is preferably done in a large cohort of women 
from the general population, thereby overcoming the criticism 
that women with normotensive pregnancies may reflect a relatively 
healthy group with a reduced risk of cardiovascular disease.6 
In this thesis we were unable to demonstrate differences in (micro)
vascular reactivity, sympathetic activity and endothelial dysfunction 
between women with a history of preeclampsia and parous con-
trols. It should be emphasized that this thesis focussed on vascular, 
metabolic and renal function after preeclampsia, which implies only 
modest appreciation for the possible contribution of other underly-
ing pathways (trombophilic, immunologic or genetic) to the risk of 
cardiovascular disease after preeclampsia.7, 8 
Pitfalls in the measurement of kidney function
Data on kidney function after preeclampsia are conflicting. On the 
one hand, several case-control studies do not support a lower kidney 
function in the first decade after preeclampsia when measured by 
creatinine clearances.9, 10 On the other hand, we know from a large 
cohort study that women with a history of preeclampsia have an esta-
blished risk on end-stage renal disease. In this thesis we found a lower 
creatinine clearance in middle-aged, perimenopausal women 23 years 
postpartum. By evaluating the individual chapters on renal function 
after preeclampsia in this thesis, we observed a lower glomerular 
filtration rate at 1 and 23 years postpartum, but not at 4 and 14 years 
postpartum. Interestingly, there was a consistent trend for a lower 
renal blood flow in women with a history of preeclampsia compared 
with parous controls at all time periods. A lower renal blood flow 
together with a higher filtration fraction suggests renal hyperfiltration 
to preserve the glomerular filtration rate. This finding was confirmed 
when comparing our data with a reference group of female kidney 
donors of similar age. Based on these findings, we postulate that the 
first decade after preeclampsia glomerular hyperfiltration may mask 
a reduced kidney function for several years. At older age or after the 
blood flow is present after preeclampsia in both young and middle-
aged women. In chapter 6, using inulin clearances in a longitudinal 
study design, we observed that the reduced glomerular filtration rate 
normalized at 14 years postpartum; however, there was a consis-
tent trend for a lower renal blood flow in women with a history of 
preeclampsia. 
Part III - Cardiovascular risk management
The third part of this thesis describes a strategy for cardiovascular 
risk management and explores possibilities for risk stratification. As 
proposed in Chapter 7, all women with a hypertensive disorder of 
pregnancy should receive postpartum a standardized cardiovascular 
risk assessment based on current guidelines for primary prevention 
in asymptomatic people. Chapter 8 outlines risk factors in a post-
partum screening for the development of chronic hypertension after 
preeclampsia, such as a family history of hypertension, a high-normal 
blood pressure and the presence of constituents of the metabolic 
syndrome. 
General discussion 
Cardiovascular health: major risk profiles
This thesis identifies two major risk profiles for cardiovascular disease 
after preeclampsia: a hypertensive and a metabolic profile. A higher 
blood pressure is observed after preeclampsia, even in women that 
do not fulfil the clinical criteria for hypertension. This was confirmed 
during the day and night by findings of 24-h ambulatory blood pres-
sure monitoring 4-6 years post partum. Subsequently, 23 years after 
preeclampsia half of the women had developed chronic hypertension. 
Chronic hypertension may cause end organ damage and is likely to be 
an important mediator in the development of cardiovascular disease 
in these women. 
The metabolic syndrome is a well-known risk factor for preeclampsia 
and cardiovascular disease. In this thesis, we observed a higher body 
mass index and insulin resistance after preeclampsia, but we did not 
discern differences in lipid profile between women with a history 
of preeclampsia and parous controls. This is in line with previous 
reports; a higher body mass index, blood pressure and insulin resis-
tance relative to parous controls are consistent findings, but several 
case-control studies were unable to demonstrate differences in lipid 
profile.1-5 Still, if present, lipid abnormalities may contribute to their 
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disorder of pregnancy, as suggested in chapter 7. For now, one could 
easily implement these guidelines to decide on what factors to screen 
for and when to treat in a postpartum screening program. Future 
research will have to prove the benefit of additional risk markers or 
specific interventions.   
Effectiveness of postpartum interventions
The first trials on postpartum lifestyle interventions are currently in 
progress, not only in women with a history of a hypertensive disor-
der of pregnancy, but also in other subgroups such women who are 
obese or experienced gestational diabetes.20-22 These trials evaluate 
weight loss, improvement of physical activity and/or cardiovascular 
biomarkers over a relatively short interval of a few months to years. 
Preliminary results suggest that such a postpartum lifestyle interven-
tion program is feasible, but more studies are necessary to assess the 
cost-effectiveness and long-term benefit.20 It remains a challenge 
in young people to demonstrate a reduction in hard cardiovascu-
lar disease (such as stroke, cardiac ischemia and thromboembolic 
events) as a result of any intervention, because of the low prevalence 
of cardiovascular disease at young age and the long follow-up period 
needed. The use of surrogate markers of cardiovascular disease could 
be helpful. Moreover, the next pregnancy is an important relatively 
short-term outcome that should be taken into account in future cost-
effectiveness studies.  
Individualized risk counselling
Individualized risk stratification following a hypertensive disorder of 
pregnancy seems particularly relevant to determine the frequency of 
follow-up and the intensity of (lifestyle-)interventions. While coun-
selling about a healthy lifestyle is recommended for all women with 
a hypertensive disorder of pregnancy, more frequent follow-up or 
intensive lifestyle interventions programs could be tailored to these 
women with the highest risk. In this thesis we identified risk factors 
for chronic hypertension after preeclampsia, showing that further risk 
stratification may be feasible. This is also suggested by epidemiologi-
cal observations, in which women with a combination of obstetric 
risk factors (preeclampsia, preterm birth and fetal growth restriction) 
have the highest risk of cardiac disease.18 Currently, we do not know 
how to weigh these additional risk factors to give an individualized 
risk estimate for cardiovascular disease after preeclampsia.19 Further 
research should evaluate this. It may be possible that the strength of 
menopause the glomerular filtration may fall, as suggested by our 
observations 23 years postpartum. However, this remains speculative 
for now and needs further investigation in larger groups.
Research on kidney function after preeclampsia is hampered by the 
low prevalence of end-stage renal disease of about 3.7/100.000, even 
though the relative risk in women with a history of preeclampsia is 
increased about 5 times.11 Moreover, both pre-existing kidney disease 
and the development of chronic hypertension may act as confoun-
ders. Our pilot study showed that it is feasible to collect longitudinal 
data using inulin clearances to determine kidney function. Still, even 
when accurate methods are used to determine glomerular filtration 
rate, this does not provide information about the filtration rate in a 
single nephron. As the measurement of single nephron glomerular 
filtration rate or nephron number is currently not feasible in humans, 
future research may focus on methods to determine renal reserve 
capacity.12, 13 
Postpartum cardiovascular screening: one step too far?  
The lack of solid data about a postpartum screening program after 
a hypertensive disorder currently hampers the implementation of 
postpartum cardiovascular screening in clinical practice. There is no 
consensus about cardiovascular screening following a hypertensive 
disorder of pregnancy. After all, screening of a population is only use-
ful when an effective treatment is available.14 Randomized-controlled 
trials are needed to prove the (cost)effectiveness of postpartum 
lifestyle intervention programs. Moreover, we need more evidence 
to reach consensus about the frequency and content of a postpartum 
screening program. Based on these arguments, one reckons that it 
is too early to implement a cardiovascular risk assessment for this 
specific group of women. 
However, with growing evidence supporting the risk of cardiovascu-
lar disease after a hypertensive disorder of pregnancy and the increas-
ing awareness of cardiovascular disease in women, women who cur-
rently have their pregnancy complicated by a hypertensive disorder 
cannot be denied any strategy for cardiovascular risk management. 
There are widely accepted guidelines available describing cardiovas-
cular risk management in asymptomatic people for primary preven-
tion of cardiovascular disease.15-17 At least a screening based on these 
guidelines can be offered to women with a history of a hypertensive 
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a model to predict cardiovascular disease risk in women increases by 
taking obstetric risk factors into account.
Conclusion
Women with a history of a hypertensive disorder of pregnancy have 
an increased risk to develop cardiovascular disease at relatively young 
age. Metabolic risk factors and the development of chronic hyperten-
sion are modifiable factors that contribute to their risk of cardiovas-
cular disease. The challenge for the future is to develop a postpartum 
cardiovascular risk management strategy that will be effective to 
promote a healthy lifestyle, improve the outcome of subsequent preg-
nancies and reduce the risk of cardiovascular disease. 
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Deel II – Nierfunctie 
Het tweede deel van dit proefschrift gaat in op de nierfunctie van 
vrouwen met een eerdere pre-eclampsie. De volgende hypothese werd 
getoetst dat de normale leeftijdsgerelateerde afname in nierfunctie 
sterker is in vrouwen die een pre-eclampsie hebben doorgemaakt 
dan bij controle vrouwen. Een vergelijking in twee cross-sectionele 
groepen vrouwen van zowel jonge als middelbare leeftijd in hoofd-
stuk 5 bevestigde deze hypothese niet, maar suggereerde juist dat er 
een verminderde kreatinine klaring en nierdoorbloeding na pre-
eclampsie aanwezig is in beide groepen. In hoofdstuk 6, gebruik 
makende van een nauwkeurige meetmethode van inuline klaringen 
in een longitudinale studie opzet, werd gevonden dat de glomerulaire 
filtratiesnelheid 14 jaar postpartum normaliseert; er was echter een 
consistente trend voor een lagere nierdoorbloeding in vrouwen met 
pre-eclampsie in de voorgeschiedenis. Een vergelijking met een groep 
vrouwelijke nierdonoren van vergelijkbare leeftijd liet een renovascu-
lair profiel zien van een verlaagde nierdoorbloeding, normale glo-
merulaire filtratiesnelheid en verhoogde filtratiefractie. 
Deel III – Cardiovasculair risicomanagement
Het derde deel van dit proefschrift zet een strategie uiteen voor 
cardiovasculair risicomanagement en verkent mogelijkheden voor 
risicostratificatie binnen deze groep. Zoals uitgewerkt in hoofdstuk 7 
zouden alle vrouwen, die een hypertensieve zwangerschapscom-
plicatie hebben doorgemaakt, in aanmerking moeten komen voor 
een cardiovasculaire risicoscreening postpartum. Deze screening 
zou moeten uitgaan van huidige richtlijnen voor primaire preventie 
van hart- en vaatziekten in asymptomatische personen. Hoofdstuk 8 
beschrijft welke risicofactoren tijdens een postpartum screening 
gerelateerd zijn aan het ontstaan van chronische hypertensie na 
preeclampsie, zoals een positieve familie-anamnese voor hypertensie, 
het herhaald optreden van een hypertensieve zwangerschapscompli-
catie en de aanwezigheid van twee of meer factoren van het metabool 
syndroom. 
Tot slot wordt in hoofdstuk 9 een algemene beschouwing gegeven 
van dit proefschrift. 
Samenvatting
Dit proefschrift onderzoekt de langetermijngevolgen van het door-
maken van een pre-eclampsie voor de cardiovasculaire gezondheid 
en nierfunctie van de vrouw. Op basis van dit proefschrift kunnen 
we concluderen dat er in de jaren na een pre-eclampsie sprake is van 
een verhoogde perifere vaatweerstand, body mass index en insuline 
resistentie in vergelijking met vrouwen die een ongecompliceerde 
zwangerschap hebben doorgemaakt. Dit profiel kan worden samen-
gevat onder de noemer ‘metabool syndroom’ en de aanwezigheid van 
een of meer van deze factoren verhoogt het risico op het ontstaan 
van hypertensie en hart- en vaatziekten. De aanwezigheid van deze 
beïnvloedbare risicofactoren suggereert dat vrouwen met een pre-
eclampsie in de voorgeschiedenis mogelijk gebaat zijn bij leefstijl- 
interventies met als doel hart- en vaatziekten te voorkomen. Om de 
gezondheid van deze vrouwen op de lange termijn te optimaliseren 
is naar onze mening een standaard cardiovasculaire risicoscreening 
na de bevalling geïndiceerd. De belangrijkste bevindingen van elk 
hoofdstuk worden hieronder samengevat. 
 
Deel I – Cardiovasculaire gezondheid
Het eerste deel van dit proefschrift beschrijft de cardiovasculaire 
gezondheid van vrouwen met een pre-eclampsie in de voorge-
schiedenis. Hoofdstuk 2 beschrijft een groep vrouwen 23 jaar na de 
bevalling, waarin de helft van de vrouwen met een pre-eclampsie in 
de voorgeschiedenis chronische hypertensie heeft ontwikkeld. Zowel 
bij de normotensieve als hypertensieve vrouwen werd een verhoogde 
renale vaatweerstand en verminderde renale doorbloeding gevonden 
vergeleken met controle vrouwen. Een verhoogde bloeddruk werd 
ook in hoofdstuk 3 bij vrouwen 4-6 jaar postpartum geobserveerd 
middels 24-uurs bloeddrukmeting. Deze studie suggereert dat waar-
schijnlijk al voor de aanvang van de zwangerschap een hogere body 
mass index en bloeddruk aanwezig waren, maar vindt echter geen 
bewijs voor een verschil in kreatinine klaring, endotheel functie of 
sympatische activiteit. Hoofdstuk 4 vindt een vergelijkbare microvas-
culaire functie na post-occlussie reactieve hyperemie in vrouwen met 
een voorgeschiedenis van pre-eclampsie en controles. Echter, er was 
een negatieve relatie tussen insuline resistentie en de microvasculaire 
functie in vrouwen met een doorgemaakte pre-eclampsie. 
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